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ABSTRACT 
PHIMON ATSAWASUWAN: Lysyl Oxidase Regulates Transforming Growth Factor-ß1 
Function in Bone 
(under the direction of Mitsuo Yamauchi) 
 
Lysyl oxidase (LOX), an amine oxidase critical for the initiation of collagen and 
elastin cross-linking, has recently been shown to regulate cellular activities possibly by 
modulating growth factor activity. In this study, we discovered that osteoblastic (MC3T3-
E1) cell-derived clones expressing higher (S) levels of LOX exhibited smaller collagen 
fibrils and lower collagen production than controls (MC, EV) while the clones expressing 
lower (AS) levels of LOX exhibited larger collagen fibrils and higher amount of collagen 
leading to subsequent defective mineralization. In order to elucidate the mechanisms by 
which collagen synthesis is controlled through LOX, we investigated the potential role of 
LOX in regulating growth factors. We further investigated the interaction of LOX with 
TGF-ß1, a potent growth factor abundant in bone, and evaluated the effect of this 
interaction.  The specific binding between LOX and TGF-ß1 was demonstrated both by 
immunoprecipitation and glutathione-S-transferase pull down assay. Both molecules 
were co-localized in the extracellular matrix in culture and the binding complex was 
identified in the mineral-associated fraction of bone matrix. Furthermore, LOX 
suppressed TGF-ß1 induced Smad3 phosphorylation and collagen (I/V) expression but 
the effects were nullified by ß-aminopropionitrile. The suppression of Smad3 
phosphorylation was not affected by the presence of catalase. The data indicate that 
LOX may bind to mature TGF-ß1 and regulate its signaling via its amine oxidase activity 
in bone, thus, may play an important role in bone remodeling and mineralization. 
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CHAPTER I 
Introduction 
Biology of bone 
Bone is a specialized form of connective tissue in vertebrates. It serves both 
mechanical and metabolic functions and is composed of two components, cellular and 
matrix components. The cellular components include bone lining cells, osteoblasts, 
osteocytes and osteoclasts while its matrix components contain organic and inorganic 
components (1, 2). Morphologically, bone is characterized either as cortical (compact) or 
as cancellous (spongy, trabecular) bone. Functionally, cortical bone provides mechanical 
resistance and strength while cancellous bone serves for mineral homeostasis and 
mechanical strength. The bone homeostatic events include bone formation, resorption 
and remodeling. 
Cellular components of bone 
The cellular components of bone are osteoblasts, osteocytes, bone lining cells 
and osteoclasts (1, 3). Osteoblasts, osteocytes and bone lining cells are derived from 
mesenchymal stem cells known as osteoprogenitor cells, whereas osteoclasts are 
derived from hematopoietic stem cells. Osteoblasts, osteocytes and bone lining cells are 
located along the surface of bone while osteocytes are located in lacuna inside the bone 
matrix (2, 3). Osteoblasts are derived from undifferentiated mesenchymal cells or 
preosteoblasts that are located in the bone marrow, endosteum and periosteum (see 
review in (4)). Bone lining cells cover most surfaces in the mature bone. They are 
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inactive and sometimes called resting osteoblasts (1, 3). The third cell type, osteocyte, is 
estimated to make up more than 90% of the bone cells in an adult bone. Immature 
osteocytes are surrounded in shallow bone matrix and closely resemble osteoblasts. As 
these cells mature and more matrices are laid down, they become located deeper within 
the bone matrix and lose their cytoplasm. They are located within a space or lacuna and 
have long cytoplasmic processes that project through canaliculi within the matrix and 
that contact processes of adjacent cells. The processes are thought to be for cellular 
communication and nutrition within a mineralized matrix (1, 2, 5). The fourth cellular 
component is the osteoclast. It is a multinucleated giant cell responsible for bone 
resorption under normal and pathological conditions. It contains many lysosomal 
vacuoles exhibiting the common description of the foamy cytoplasm. The plasma 
membrane of the active osteoclast has an infolded appearance known as a ruffled 
border. It works as a seal to create microenvironment for bone resorption (3, 6). For the 
development of osteoclast, crosstalk between osteoblasts and osteoclasts must exist to 
coordinate the process of bone formation and resorption. Osteoprotegerin (OPG) was 
discovered to be secreted by osteoblasts and acts as a soluble competitive binding 
partner for RANKL (receptor/activator of NF-B ligand), which inhibits osteoclast 
formation and consequently bone resorption. Both OPG and RNAKL can bind to RANK 
(receptor/activator of NF-B); a transmembranous receptor expressed on osteoclast 
precursor cells.  Interaction between RANKL and RANK initiates a signaling and gene 
expression cascade resulting in the promotion of osteoclast formation from the precursor 
pool (7-9).  
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Extracellular components of bone 
The extracellular matrix (ECM) in bone is composed of organic and inorganic 
components. The organic matrix accounts for approximately 35% of the total weight of 
bone tissue compared with 65% for the inorganic part (3).  
The inorganic component is generally referred to as hydroxyapatite 
(Ca10(PO4)6(OH)2), a plate-like crystal 20-80 nm in length and 2-5 nm thick. Because 
bone apatite is four times smaller than naturally occurring apatites and less perfect in 
structure, it is more reactive and soluble and facilitates chemical turnover (10).  
The freshly synthesized matrix prior to its mineralization, osteoid, consists 
primarily (approximately 94%) of collagen type I and is secreted by osteoblasts. Major 
non-collagenous proteins in bone consist of proteoglycans. In addition to their role in 
defining the spatial organization of the ECM, type I collagen interacts with growth factors 
during the development (11). Osteocalcin, osteopontin, osteonectin and matrix-gla 
protein play roles during the mineralization process (12, 13). Other proteins such as 
bone morphogenic proteins, growth factors, cytokines, and adhesion molecules also play 
roles in bone homeostasis (11).  
Collagens in bone 
Collagens are a large family of structurally related proteins that assemble in the 
ECM and contain one or more domain(s) of unique triple helices (collagenous domain). 
This collagenous domain, the hallmark of these proteins, is a coiled-coil right-handed 
triple helix composed of three polypeptide chains, called  chains. The non-triple helical 
domains are called non-collagenous domains. Each  chain in the molecule is coiled into 
an extended left-handed polyproline II-type helix and then the three left-handed helical  
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chains are intertwined to one another and folded into a ropelike right-handed triple helix 
structure (14). The triple helical structure is stabilized by the high content of imino acids, 
i.e. proline (Pro) and hydroxyproline (Hyp) and the presence of Hyp is essential for 
interchain hydrogen bonds that further stabilize the triple helical structure. Collagen 
molecules consist of the repetitive sequences of amino acids [Gly(glycine)-XY]n (X and Y 
can be any amino acid but often X is Pro and Y Hyp) are required. Every third amino 
acid is situated in the center of the triple helix in a very restricted space where only Gly, 
the smallest amino acid, can fit (15). Collagen is the most abundant protein in 
vertebrates accounting for about 30% of the body’s total proteins and is present in 
essentially all tissues and organs of the body. The collagen superfamily consists of 27 
different genetic types and these distinct types of collagen show marked diversity and 
complexity in the structure, their biological function and tissue distribution. The collagen 
superfamily can be divided roughly into 3 groups: fibril forming (type I, II, III, V, XI, XXIV 
and XXVII), fibril-associated collagen with interrupted triple helices (FACIT) (type IX, XII, 
XIV, XVI, XIX, XX, XXI, XXII and XXVI), and non-fibril forming (type IV, VI, VII, VIII, X, 
XIII, XV, XVII, XVIII, XXIII, XXV and XXVI)(15-19). In bone, type I collagen is the most 
predominant type of collagen and type V collagen is present as a minor type. Type I 
collagen is a heterotrimeric molecule composed of two 1 chains and one 2 chain, 
[1(I)]22(I), although a homotrimeric form of 1 chains [1(I)]3, does exist as a minor 
form. The precursor molecule called tropocollagen consists of three domains: the NH2-
terminal nontriple helical (N-telopeptide), the central triple helical and the COOH-terminal 
nontriple helical (C-telopeptide) domains. The procollagen is secreted outside the cell as 
its precursor form. Proteolytic cleavage of the propeptides results in mature collagen 
molecules and can assemble into fibrils (20-22). The biosynthesis of procollagen is a 
complex process in which several enzymes and molecular chaperones assist its folding 
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and trimerization (23, 24). A number of posttranslational modifications occur both at 
intra- and extracellular locations. Protein disulphide isomerase (PDI) induces the 
formation of inter- and intrachain disulphide bonds within the C-propeptide, allowing the 
association between procollagen chains (25, 26). The C-propeptide ensures the 
association between monomeric and heteromeric procollagen chains. Newly synthesized 
procollagen chains are associated in trimers through their C-propeptides, leading to 
nucleation and folding in a C-to-N direction to form a triple helix. The biosynthesis of 
procollagen involves different posttranslational modifications that occur in the 
endoplasmic reticulum: peptidylproline cis-trans isomerase is required to convert the 
proline residues to the trans form (27, 28), and prolyl 4-hydroxylase is required to 
convert proline into hydroxyproline residues (29, 30). The family of lysyl hydroxylase 
(LH) contributes to the formation of hydroxylysine, which specific residues at telopeptide 
can subsequently be further modified by lysyl oxidases (LOXs). The collagen chaperone 
heat shock protein (HSP) 47 is also required for the folding of the collagen (31, 32). All of 
the enzymes responsible for these modifications work in a coordinated fashion to ensure 
the folding and assembly of a correctly aligned and thermally stable triple-helical 
molecule. During the secretion of these molecules into the ECM, propeptides are 
removed by procollagen N- and C- proteinases (NCP and PCP), thereby allowing 
spontaneous self-assembly of collagen molecules into fibrils (33). Finally, the triple-
helical structure is stabilized by an important posttranslational modification that allows 
intra/intermolecular cross-links to take place as a result of the catalysis of lysyl oxidase 
(LOX), which oxidizes the specific lysine (Lys) and hydroxylysine (Hyl) residues at the 
telopeptidyl domains of collagen molecules (Figure 1.1)(15, 34-36). 
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Figure 1.1 Schematic for the biosynthesis of type I collagen. The upper part shows the 
intracellular events and the lower part shows the extracellular events. The intracellular events 
include extensive post-translational modifications such as Pro- or Lys- hydroxylation, 
glycosylation, association of pro  chains and folding into a triple helical molecule from the C- to 
N-terminus. The extracellular events involve the removal of both N- and C-propeptides, self-
assembly of collagen molecules into fibril, enzymatic oxidative deamination of lysine and 
hydroxylysine residues by lysyl oxidase (LOX) and subsequent intra- and intermolecular covalent 
cross-linking (15). 
Cross-linking pathway 
The process of cross-linking is initiated by the oxidative deamination of ε-amino 
groups on peptidyl Lys and Hyl residues in the N- and C-terminal telopeptides of 
collagen and Lys in elastin (34, 37). This reaction generates 5-amino-5-carboxypentanal 
[(α-aminoadipic acid-δ-semialdehyde) (Lysald)] and 2-hydroxy-5-amino-5-
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carboxypentanal [(δ-hydroxy, α-aminoadipic acid-δ-semialdehyde) (Hylald)] and ammonia 
(NH3) and hydrogen peroxide (H2O2) (Figure 1.2), and initiates a series of condensation 
reactions forming covalent intra- and intermolecular cross-links (15, 38, 39). Covalent 
intermolecular cross-linking is essential to provide the tissues with mechanical properties 
to perform their structural functions. In collagen, once the aldehydes (either Lysald or 
Hylald) are formed by the action of LOX in the C- and the N- telopeptide domains, they 
undergo a series of condensation reactions involving another aldehyde in the same 
molecule and/or the juxtaposed Lys, Hyl and histidine (His) residues on the neighboring 
molecules. The results are the formation of covalent intra- and intermolecular cross-links 
as shown in figure 1.3 (15, 38-40). The cross-linking chemistry/pattern varies from tissue 
to tissue rather than particular collagen types since a number of tissue specific factors 
govern the chemistries. Depending on the state of hydroxylation of Lys residues at 
telopeptides, two major cross-linking pathways evolved Lysald and Hylald pathways. 
Besides the enzymatic cross-linking mentioned above, the non-enzymatic cross-linking 
of collagen has also been taken place (see review in (41-44)).    
 
Figure 1.2 The sites and reaction of LOX on collagen molecules. The specific Lys or Hyl at 
telopeptidyl domain of a collagen molecule which can be oxidized by LOX and the reaction of 
LOX oxidation in the presence of oxygen (O2) and water (H2O). The end products are Lys
ald
 or 
Hyl
ald
, ammonia (NH3) and hydrogen peroxide (H2O2)(15). 
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The Lysald pathway, a major cross-link pathway in non-mineralized tissues, leads 
to the formation of a tetravalent cross-link, dehydrohistidinohydroxymerodesmosine 
(deH-HHMD, Lysald x Lysald x His x Hyl) via intramolecular aldol condensation product 
(ACP), and a trivalent stable cross-link, histidinohydroxylysinonorleucine (HHL, Lysald x 
Hyl x His) via the iminium cross-link, dehydro-hydroxylsinonorleucine (deH-HLNL, Lysald 
x Hyl). ACP (α,ß-unsaturated aldol) occurs as an intramolecular cross-link located in the 
N-telopeptide domain of the molecule (45, 46). Then Michael addition of N3 imidazole of 
His to the ß-carbon of ACP resulting as aldolhistidine and further condenses with ε-
amino group of Hyl forming an iminium bond to produce deH-HHMD (46). The deH-
HHMD is abundant in skin. Lysald located in the C- and N-telopeptide domains can also 
cross-link to the juxtaposed ε-amino group of helical Hyl or Lys on the neighboring 
molecules to form iminium intermolecular cross-links, deH-HLNL. Then deH-HLNL 
further condenses with a helical His residue and forms the HHL cross-link (47). This HHL 
cross-link is abundant in skin and cornea (48) but minimal in skeletal tissues such as 
dentin, bone, ligament and tendon (49). 
The Hylald pathway, a major cross-link pathway in skeletal tissues such as bone, 
cartilage, tendon and dentin leads to the formation of bifunctional cross-links; dehydro-
dihydroxylysinonorleucine (deH-DHLNL, Hylald x Hyl) and deH-HLNL (Hylald x Lys), and 
condenses to tri-functional cross-links; pyridinoline (Pyr, Hylald x Hyl x Hylald), pyrrole (Prl, 
Hylald x Hyl x Lysald), deoxy-pyridinoline (d-Pyr, Hylald x Lys x Hylald), and deoxy-pyrrole 
(d-Prl, Hylald x Lys x Lysald) (15). The deH-DHLNL can spontaneously form its 
ketoamines by Amadori arrangement, and further matures into Pyr by involving Hylald or 
another deH-DHLNL/or its ketoamine (38). Prl can be formed by pairing deH-DHLNL 
with Lysald. This cross-link pathway also leads to deH-HLNL (Hylald x Lys) which further 
condenses with Hylald to form d-Pyr or condenses with Lysald to form d-Prl (15). As 
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described above, the final post-translational modification of collagen is cross-linking 
formation and this process is initiated by LOX enzymes. 
 
Figure 1.3 Major cross-linking pathways in type I collagen. L.H.: Lysyl hydroxylase, LOX: Lysyl 
oxidase, ACP: Aldol condensation product (Intramolecular cross-link), deH: dehydro HLNL: 
hydroxylysinonorleucine, DHLNL: dihydroxylysinonorleucine, HHMD: 
histidinohydroxymerodesmosine, HHL: histidinohydroxylysinonorleucine, Pyr: pyridinoline, d-: 
deoxy, Prl: pyrrole. (15) 
Lysyl oxidases 
Lysyl oxidases (LOXs; EC1.4.3.13; protein-lysine 6-oxidases) are extracellular 
copper (Cu2+)-dependent amine oxidases that oxidize the ε-amino groups on the specific 
Lys and Hyl of collagen and Lys in elastin (34, 37). This enzyme was first demonstrated 
its activity in vitro in 1968 (50) but many studies on this enzyme were limited by its 
marked insolubility and aggregation which later was solved by solubility and stability in 
urea (51). The molecular mass of the enzyme from tissues such as cartilage, aorta, lung, 
placenta and skin was found to be approximately 32 kDa (52-56). Lysyl oxidase 
extracted from several tissues resolved upon DEAE chromatography into multiple forms 
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(57). This suggested the existence of alternative spliced or the presence of isozymes 
with similar but not identical properties. The human LOX gene is located in chromosome 
5q23.3-31.2 encoding a 417 amino acid polypeptide, of which the first 21 residues 
correspond to the signal peptide (58, 59) and the mRNA for human LOX is found as 
multiple species with sizes of 5.5, 4.3, 2.4 and 2.0 kb due to the use of alternate 
polyadenylation sites, and partially to the existence of multiple transcription initiation 
sites (58-60). The mouse Lox gene has been mapped to chromosome 18 (61-63). 
Biosynthesis and processing of the LOX precursor 
LOX protein is secreted into the extracellular space (64-68). The biosynthesis of 
LOX proenzyme has been first proved by immunoprecipitation of a 46 kDa cell-free 
translation product of a rat smooth muscle cell LOX mRNA, using an antibody raised 
against the 32 kDa bovine enzyme (69, 70), and a 48 kDa product, using mRNA isolated 
from fibrotic rat liver (71). Three forms of LOX with molecular masses of 50, 47, and 32 
kDa were identified by immunoprecipitation of media and cell layer extracts of cultured 
rat smooth muscle cells, which were pulse-labelled with [35S] methionine (72). The 50 
kDa product was found both as a secreted protein in the cell medium and in the 
intracellular fraction, and pulse-chase studies revealed that it is converted to a 32 kDa 
protein in the medium. The LOX protein is synthesized as a N-glycosylated derivative of 
the 45 kDa proprotein (72), ~50 kDa proLOX by various cell types including 
normal/transformed fibroblasts, endothelial cells, smooth muscle cells and osteoblasts 
(73-79). The mouse and rat propeptide domain contains two consensus sites for the 
posttranslational N-glycosylation (72). The 32 kDa active enzyme, LOX, contains the 10 
cysteine residues of proLOX, all of which exist in disulfide linkage (80). The secreted 
proLOX is catalytically quiescent but is activated through proteolytic cleavage by 
procollagen C-proteinases (PCP/BMP1) between residue Gly168 and Asp169 (numbered 
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according to the human sequence) (81, 82), that may occur at cell surface in a bound 
complex with cellular fibronectin (83). It was also found that other extracellular 
proteases, including mammalian tolloid (mTLD) and tolloid-like-1 and 2 proteases 
(mTLL-1 and -2) cleaved proLOX at the correct physiological site but at lower efficiency 
(84). The N-terminal propeptide of LOX has been implicated in regulating the localization 
of the enzyme within the specific matrix (85) and reversion of ras-transformed cells to 
the non-oncogenic phenotype (86). 
The C-terminal of human LOX is homologous to the N-terminal extracellular 
domain of the growth factor and cytokine receptor superfamily and this domain overlaps 
the catalytic site. The consensus sequence found in the N-terminal modules of Class 1 
receptors, C-x9-C-x-W-x26-32-C-x10-13-C (where C is cysteine, W is tryptophan, and Xn is a 
defined number of any amino acid), is conserved in human LOX (87). The cytokine 
receptor module is known to play an adhesion role in several proteins of the growth 
factor and cytokine receptor superfamily. Based on structure prediction, the cytokine 
receptor-like domain in the LOX protein forms a partial receptor site and it is 
questionable if it binds cytokines in the same way (88). 
Catalytic mechanism 
Cofactor 
The activity of (mature) LOX requires two cofactors, copper (Cu2+) and lysyl 
tyrosylquinone (LTQ). Direct evidence that copper is a component of LOX was obtained 
from enzyme isolated from chick bone (89, 90), chick aorta (91, 92), and bovine aorta 
(93). Studies have demonstrated that approximately one tightly bound copper atom is 
present in the mature 32 kDa and the removal of the copper ion leads to a catalytically 
inactive apoenzyme. Electron spin resonance studies have indicated that the copper in 
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the resting enzyme is in the Cu(II) state, and is bound tetragonally distorted, octahedrally 
coordinated ligand field (93). The sequence WEWHSCHQHYH in human has been 
suggested to be the actual copper-binding region, which provides four histidine residues 
that are involved in the copper-binding coordination complex (94). In addition to the 
tightly bound Cu ion, purified LOX preparations have been shown to contain 5-9 atoms 
of loosely bound copper per enzyme molecule (93). Experiments in a cell free 
transcription/translation system in vitro have shown that the unprocessed 50 kDa LOX 
precursor binds copper (95). A study showed that protein synthesis was important for the 
incorporation of copper into enzyme but N-linked glycosylation had no effect on 
secretion of the copper that was bound to LOX. In addition, an inhibition of processing of 
the 50 kDa LOX precursor into the 32kDa active form with a PCP inhibitor had minimal 
effect on the amount of copper that was bound to LOX in the cell media (95). Kagan et. 
al. in 1995 (96) has shown that the propeptide region is not essential to the folding and 
secretion of the functional enzyme. A truncated rat LOX cDNA lacking sequences which 
encode for the bulk of the propeptide region was transfected into Chinese hamster ovary 
cells. The 29 kDa form of mature LOX which catalyzed the deamination of human 
recombinant tropoelastin and alkylamines was secreted and this secreted enzyme could 
be inhibited by ß-aminopropionitrile (ßAPN). However, the expression analysis of 
recombinant LOX in myofibroblast-like cells showed that propeptide region was 
important for the secretion (97). These controversial data might be due to the difference 
of type of promoter of the vectors used in the study. These results indicated that copper 
is incorporated into proLOX in the endoplasmic reticulum or during protein trafficking 
through the Golgi elements and independent to glycosylation (95, 98).  
In addition to copper, LOX was known to possess a covalently bound carbonyl 
prosthetic group called LTQ (99-104). LTQ is likely the product of a self-processing 
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reaction involving Cu2+-mediated/assisted oxidation of a specific peptidyl tyrosine (res 
345 in ratLOX) followed by covalent cross-linking with the ε-amino group of a conserved 
peptidyl Lys (res 314 in rat LOX)(105, 106). This unique intramolecular cross-link, LTQ, 
together with several disulfide linkages within the LOX molecules, most likely contributes 
to the remarkable physicochemical stability of LOX (34, 104). The covalently linked lysyl 
component of LTQ of LOX might play an important role in the preference of LOX for 
peptidyl lysine substrates in cationic protein microenvironments both as a result of its 
donation of anionic charge to the active site and possibly by restricting the rotation of the 
LTQ ring in a manner that properly orients the carbonyl cofactor with respect to peptidyl 
lysine substrates (104). LTQ could be formed in the endoplasmic reticulum or during 
protein trafficking through the Golgi apparatus (98)(Figure 1.4)  
The mechanism of action of LOX has been described in many studies (93, 100, 
107-109). The ε-amino group of the substrate lysine residue condenses with one of the 
two carbonyls of LTQ to form a Schiff base. The Schiff base linkage coupled with 
general base-assisted abstraction of hydrogen on carbon 6 of the substrate lysine 
residue permits the flow of two electrons into LTQ generating the reduced peptidyl lysine 
tyrosyl aminoquinol. A histidine has been suggested to act as the general base in LOX 
(110). Hydrolysis of the resulting imine linkage releases the peptidyl aldehyde product 
from the reduced cofactor. This reactive aldehyde product can then react spontaneously 
to form lysine- or hydroxylysine-derived cross-links. Subsequent reoxidation of the 
peptidyl aminoquinol occurs by transfer of two electrons to molecular oxygen, forming 
and releasing hydrogen peroxide. The quinoeimine so formed is then hydrolyzed to 
regenerate LTQ and to release the free ammonia product of the reaction (111).  
 
 14 
Figure 1.3 Pathway for LOX biosynthesis. The LOX precursor is trafficked into the rough 
endoplasmic reticulum where its signal peptide is cleaved. The precursor is glycosylated within 
the endoplasmic reticulum at two possible Asn residues located in the propeptide region. The 
addition of copper (Cu
2+
) and the formation of LTQ cofactor consequently occur. After secretion of 
the LOX precursor into the ECM, the propeptide region is cleaved by procollagen C-proteinase 
(PCP) between Gly-168 and Asp-169 to obtain and an active 32 kDa enzyme. Lysyl oxidase 
propeptide (LOPP) and mature LOX has been reported to enter the cell and nucleus after 
secretion. Molecular mass of LOX polypeptide is indicated according to human LOX enzyme. (69, 
70, 112, 113). Cu: Copper, LTQ: Lysyl tyrosylquinone. 
Inhibitors 
ßAPN, a potent lathyrogen which can inhibit cross-linkage formation in vivo, was 
recognized before the identification of LOX activity in vitro (114). ßAPN was identified as 
an active agent in Lathyrus oderatus peas causing abnormalities in animals including 
aortic aneurysm, skin abnormalities, bone and joint weakness (115). Administration of 
ßAPN to growing animals results in a condition known as lathyrism, which is 
characterized by an increased fragility of all connective tissues and an increased 
solubility of collagen from the tissues (see section osteolathyrism). It has been first 
demonstrated that micromolar of ßAPN irreversibly inhibited the activity of LOX in vitro 
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(50). ßAPN was found to be a potent irreversible inhibitor and its inhibition was 
temperature- and time-dependent (116). ßAPN binds to the LTQ, the active site of LOX, 
and forms a dead-end complex. A free aldehyde product was not generated and the 
copper content of LOX was not altered upon incubation with ßAPN (117, 118). ßAPN 
has been used to specifically as a lysyl oxidase inhibitor. ß-haloamines and ß-
nitroethylamine are also reported as mechanism-based irreversible inhibitors of LOX 
similar to ßAPN (119). Benzylamine derivatives containing para substituents of 
increased electronegativity and isomers of aminomethypyridine are also identified as 
reversible ground state inhibitors by forming LOX-bound intermediates that are not 
completely processed into aldehydes (107). Vicinal diamines like cis-1,2-
diaminocyclohexane and ethylenediamine are potent irreversible inhibitors (120). LOX is 
inhibited by heparin (121), N-(5-aminopentyl) azidine (122), and trans-2-
phenylcyclopropylamine (123). LOX is inhibited by homocysteine thiolactone and its 
selenium and oxygen analogs in an active-site-directed and irreversible manner (124). 
LOX is inhibited by ascorbic, and esthoric acids and 3,4-dihydroxybenzoate by possibly 
the ascorbic acid structure (125). 
Substrate specificity 
It was long believed that soluble precursors and immature elastin and fibrillar 
collagen were the only biological substrate of LOX. This knowledge has been revised 
when in vitro assays demonstrated that the purified LOX oxidized a number of basic 
globular proteins with pI values > 8.0, but did not oxidize neutral or acidic globular 
proteins with pI value < 8.0 (126). The electrostatic potential between LOX and its basic 
protein substrates was essential to productive catalysis. LOX also oxidizes non-peptidyl 
amine substrates such as n-butylamine and 1,5-diaminopentane leading to the 
 16 
development of fluorescence-based assay for LOX-dependent H2O2 production (127, 
128). 
The sequence region within the LTQ domain between Lys314 and Tyr349 are 
enriched in anionic residues. Once these two regions of LOX become covalently cross-
linked to each other as the LTQ cofactor is generated, both of these regions would 
cooperatively provide an abundance of negatively charged sites in the microenvironment 
of the active site. It is likely that such an arrangement underlies the strong preference of 
LOX for cationic protein substrates (104). Interestingly, the sequences surrounding the 
susceptible lysines in collagen are in hydrophilic sequences containing anionic residues. 
For example, the lysine residue within the Asp-Glu-Lys-Ser sequence which occurs at 
the N-terminal region of the α1(I) collagen chain within the mature type I collagen 
molecule is oxidized by LOX in vivo. However, a collagen-like synthetic peptide which 
contains the similar sequence was not a good substrate in assays in vitro and oxidation 
occurred if the Asp residue was replaced with a Gly residue (129). This observation 
leads to the suggestion that collagen molecules must form into microfibrils before their 
oxidation by LOX (130) and binding domain of LOX is located in the helical portion of 
collagen molecule (131). These results led to the hypothesis that the unfavorable 
negative charge contributed by this Asp residue can be neutralized by a specific cationic 
site in the neighboring collagen molecule within the quarter-staggered microfibril, thus 
allowing lysine oxidation by LOX (129). It has been reported that the propeptide regions 
of recombinant proenzyme of LOX mediated the binding of these enzymes to soluble 
precursor and fibrous form of elastin in the cultures of transfected RFL-6 fibroblasts. It 
leads to the conclusion that the binding of the LOX proenzymes to elastin substrates 
was essential for the oxidation of lysine in elastin by the activated LOX (85). It has been 
reported that proLOX can bind to fibronectin (FN) to be proteolytically activated to the 
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functional catalyst (83). Histone H1 and H2 have been demonstrated to have an 
interaction with LOX in vitro  (132) and incubation of Histone H1 with LOX results in the 
catalytic formation of hydrogen peroxide implicating that histone H1 is a substrate of 
LOX (133). Basic fibroblast growth factor was reported to be a substrate of LOX as the 
oxidation of lysine residues in bFGF by LOX resulted in the covalent cross-linking of 
bFGF monomers to form dimers and higher order oligomers and dramatically altered its 
biological properties (134). Recently, LOX has been reported to be essential for hypoxia-
induced metastasis because the administration of ßAPN, specific anti LOX antibody or 
short hair-pin RNA could inhibit the metastasis in animal model. It is still unclear whether 
LOX might oxidize an unknown key protein and inhibit its function in the cancer 
metastasis, or whether the by-product H2O2 from the oxidation plays a role in the 
inhibition of cancer metastasis (135). 
Regulation of LOX 
The factors that were reported to play roles in the regulation of LOX gene 
expression are transcriptional factors and growth factors as shown in Table 1.1. 
Table 1.1 The various regulators and effects on LOX mRNA and enzymatic activity.  
Effector (reference) Cell or tissue Effect 
IFN- (136) Rat aortic smooth muscle cells Down regulation of mRNA; 
decreased mRNA half-life 
bFGF (75) Mouse osteoblastic cells Decreased mRNA level (1-10nM) 
upregulated of mRNA (0.01-0.2 
nM) 
FGF-2 and IGF-1 (137) Inflamed oral tissue, rat 
fibroblastic mesenchymal cells 
Increased of mRNA 
PGE2 (138-140) Rat lung fibroblasts 
Human embryonic lung 
fibroblasts 
Unchanged mRNA level; 
reduction in enzyme activity 
Downregulation of mRNA 
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TGF-ß1 (75, 76, 138, 
139, 141-146) 
Rat aortic smooth muscle cells  
human gingival fibroblast, flexor 
reticulum cells, renal cell lines, rat 
lung fibroblasts, kidney tubular 
epithelial cells, mouse 
osteoblasts 
Increased mRNA level and 
enzyme activity 
BMP-2 (147) Murine pre-myoblast cells Increased mRNA level 
TNF- (79, 148) Mouse osteoblastic cells          
                                             
Aortic endothelial cells 
Decreased mRNA, protein level 
and enzymatic activity 
Decreased mRNA and level and 
enzymatic activity 
Cadmium (149) Mouse fibroblasts 
Mouse cadmium-resistant 
fibroblasts 
Decreased mRNA level 
Increased mRNA level 
Testosterone (150, 151) Calf aortic smooth muscle cells, 
rat granulosa cells 
Increased enzyme activity and 
increase mRNA expression 
Follicle stimulating 
hormone (151) 
Rat granulosa cells Decrease mRNA expression and 
enzyme activity 
Growth differentiation 
factor-9 (151) 
Rat granulosa cells Increase mRNA expression and 
enzyme activity 
Activin A (151) Rat granulosa cells Increase mRNA expression and 
enzyme activity 
Bleomycin (152) Human lung fibroblasts 
Human dermal fibroblasts 
Increased mRNA level 
Decreased mRNA level 
Hydralazine (152) Human dermal fibroblasts Increased mRNA level 
Minoxidil (152) Human dermal fibroblasts Increased mRNA level 
Adriamycin (153) Rat kidney glomeruli, medulla Increased mRNA level 
cAMP (140, 154) Rat and human vascular smooth 
muscle cells 
Upregulated of transcription 
PDGF (155) Rat vascular smooth muscle cells Upregulation of mRNA 
Dexamethasone (156) Cultured fetal murine lungs Upregulation of mRNA 
Retinoic acid (157) Adipocytes in early adipogenesis Prevents downregulation of 
mRNA and enzyme activity. 
Hypoxia inducible factor-
1 (158) 
Breast cancer cells Increased mRNA and protein 
level but decreased enzymatic 
activity 
Hypoxia/reoxygenation Breast cancer cells Increase mRNA, protein level 
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(158) and enzyme activity 
Low density lipoprotein 
(77) 
Vascular endothelial cells Decrease mRNA expression and 
enzyme activity 
Homocysteine (159) Vascular endothelial cells Decrease LOX activity (35 M) 
Decrease LOX mRNA 
expression and LOX promoter 
activity (250M) 
Pulsed ultrasound (160) Mouse osteoblastic cells Increase LOX mRNA expression 
and enzyme activity (30 mW/cm
2
) 
Metavanadate (161) Rat fibroblast Decrease LOX activity 
Modified from (88, 162)  
Animal models 
The consequence of inactivation of the Lox gene in mice results in neonatal 
lethality (162-164). The mice develop to full term but are not viable. The autopsy 
revealed large aneurysms in aorta, which the diameter of aneurysm was 3 times larger 
than in the aortas of the wild-type littermates and the wall of the aorta in the Lox-/- 
animals was significantly thicker but the diameter of the aortic lumen was significantly 
smaller than those in the wild-type littermates. The Lox-/- animal had a congenital 
diaphragmatic hernia and a large hemorrhage in the upper chest region. Microscopic 
analysis showed abnormal elastic lamellae with fragmented elastic fibers and 
discontinuity in the smooth muscle cell layers in Lox-/- fetuses (162, 163). Another report 
on Lox-/- animals reported the similar phenotypes as that the animal died soon after 
parturition, exhibiting cardiovascular instability with ruptured arterial aneurysms and 
diaphragmatic rupture. Microscopic analysis of the aorta demonstrated fragmented 
elastic fiber architecture in homozygous mutant null mice. LOX activity, as assessed by 
desmosine (elastin cross-link) analysis, was reduced by approximately 60% in the aorta 
and lungs of homozygous mutant animals compared with wild type mice. Immature 
collagen content in aorta and lungs of the animals were decreased 74% and 68% 
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respectively compared with those of wild-type littermates. There were significant 
decreases in DHLNL and HLNL of 43 and 39% respectively in the Lox-/- animals as 
compared with wild type total body collagen cross-links. Interestingly in Lox+/- mice, 
DHLNL was 100% of wild type, while HLNL was only 64% of wild type content. This 
could represent a greater role for LOX in HLNL cross-links. Moreover, DHLNL in lung of 
Lox-/- animals was not different among genotypes while decreased in HLNL in Lox+/- 
and Lox-/- was 14 and 32% respectively (164). 
Lysyl oxidase isoenzymes 
Isoenzymes or isozymes are defined as isoforms of enzymes in biochemistry. 
They are the enzymes that differ in amino acid sequence but catalyze the same 
chemical reaction (165). They are present in different tissues, cell types, or 
developmental stages of the same or different tissues or organs. Four LOX-like (LOXL) 
proteins varying degree of similarity to LOX have been discovered and identified; lysyl 
oxidase-like protein (LOXL1) (87, 166), lysyl oxidase-like 2 protein (LOXL2) (167, 168), 
lysyl oxidase-like 3 protein (LOXL3) (162, 169-172), and lysyl oxidase-like 4 protein 
(LOXL4) (162, 173-175). Polypeptides of all these isozymes are highly conserved within 
their C-terminal ends, which include the copper-biding sites, cytokine receptor-like 
domains, and LTQ cofactor sites (88). All LOXL proteins possess amine oxidase activity 
(174, 176-178). In LOXL2, 3 and 4, repeated scavenger-receptor cysteine-rich (SRCR) 
domains are present as conserved domain. These domains have the potential to interact 
with other proteins. The SRCR domain contains either six or eight cysteine residues 
located at highly conserved positions important for tertiary conformation and is found in 
cell surface protein or secreted protein associated with the immune system. The 
comparison of LOX family member is shown in the table 2 (adapted from Hornstra et al 
2003(164)). 
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Table 1.2  The comparison of LOX family member. 
Family 
member 
Human 
Chr. 
Mouse 
Chr. 
mRNA 
and 
protein 
size 
Highest mRNA 
tissue 
distribution 
Protein 
domains 
%similarity 
to LOX 
domain 
%similarity 
to LOXL2 
domain 
LOX 5 18 6.8, 4.8 kb 
417 res. 
Lung, skeletal 
muscle, kidney, 
heart 
Amine 
oxidase 
100 63 
LOXL1 15 9 2.4 kb    
574 res. 
Lung, heart, 
spleen skeletal 
muscle, 
pancreas 
Amine 
oxidase 
85 63 
LOXL2 8 14 4.0 kb  
774 res. 
Lung, thymus, 
skin, testis, 
ovary 
4 SRCR, 
Amine 
oxidase 
58 100 
LOXL3 2 6 3.3 kb 753 
res. 
Heart, uterus, 
testis, ovary 
4 SRCR, 
Amine 
oxidase 
65 78 
LOXL4 10 19 3.5 kb 756 
res. 
Skeletal muscle, 
testis, pancreas 
4 SRCR, 
Amine 
oxidase 
62 79 
 
Lysyl oxidase-like protein (LOXL1) 
LOXL1 has been first discovered from a novel human cDNA with a predicted 
protein similar to LOX. The LOXL1 cDNA corresponds to a single polyadenylated mRNA 
species of 2.5 kb, which shows a concomitant expression with LOX mRNA in several 
human tissues (87). The LOXL1 polypeptide consists of 574 amino acids, with a 
calculated mass of 63 kDa. It shows 76% similarity with LOX at its C-terminal region (87, 
166), which includes the copper-binding site and the four histidine residues with the 
conserved sequence (WEWHSCHQHYH) that are involved in the copper binding 
complex. In addition the cytokine receptor-like sequences are present in this C-terminal 
region in both LOX and LOXL1 polypeptides. The LOXL1 gene contains 7 exons and 
has been mapped to chromosome 15q24 in humans (179) and chromosome 9 in mice 
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(180, 181). LOXL1 protein is a secretory protein that is expressed in active fibrotic 
diseases and in the early stromal reaction of breast cancer (182). Coincident 
appearance of increased steady-state levels of LOXL1 and COL3A1 mRNAs was 
detected in the early development of liver fibrosis, suggesting that LOXL1 protein is 
involved in the development of lysine-derived cross-links in collagenous substrates. In 
contrast, steady-state levels of LOX mRNA were increased throughout the onset of 
hepatic fibrosis and appeared in parallel with increased steady-state level of COL1A1 
mRNA (183). A specific antibody against LOXL1 has been used to identify proteins 
immunochemically distinct from LOX in various cells and in bovine aorta. The species of 
the protein are approximately 68, 52, 42 and 30 kDa (182). A 56 kDa LOXL1 protein was 
isolated from bovine aorta and the precursor needs to be cleaved by BMP-1 to be active 
(176). The mice lacking LOXL1 do not deposit normal elastic fibers in the uterine tract 
post partum and develop pelvic organ prolapse, enlarged airspaces of the lung, loose 
skin and vascular abnormalities with concomitant tropoelastin accumulation. Distinct 
from the prototypic LOX, LOXL1 localizes specifically to sites of elastogenesis and 
interacts with fibulin-5. Thus elastin polymer deposition is a crucial aspect of elastic fiber 
maintenance and is dependent on LOXL1, which serves both as a cross-linking enzyme 
and an element of the scaffold to ensure spatially defined deposition of elastin (184). 
Lysyl oxidase-like protein 2 (LOXL2) 
LOXL2 was originally cloned, characterized, and named as WS9-14 for its 
possible association with Werner syndrome (167). Later it was found that WS9-14 
mRNA corresponds to LOXL2 mRNA but WS9-14 transcript encodes one additional 
SRCR domain in its 5’ end region (88, 168). LOXL2 mRNA encodes an 87 kDa 
polypeptide, which contains four SRCR domains that are found in several secreted and 
cell surface proteins (167). LOXL2 polypeptide shares a 48% similarity with the LOX 
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polypeptide in its amino acid sequence from residue 546 to 751 in its C-terminal region. 
This region contains all conserved amino acid sequences needed for the proper function 
of the mature 32 kDa form of LOX enzyme (167, 168). LOXL2 gene has been mapped to 
chromosome 8p21 in humans (185) and chromosome14 in mice (186), and it consists of 
at least 11 exons (168). LOXL2 is abundantly expressed in senescent fibroblasts and 
several adherent tumor cell lines, but is down-regulated in several non-adherent tumor 
cells. This suggests that it may be involved in cell adhesion and that a loss of this protein 
may be associated with the loss of tumor cell adhesion leading to tumor metastasis. 
LOXL2 shows similar spatial expression with LOX and LOXL in human placenta and 
fetal tissues in early pregnancy. However, this pattern diverges during gestation (187). In 
full-term human placenta, LOX is expressed predominantly in the amniotic epithelium, 
with little expression in the placenta, while LOXL shows the highest expression in the 
placenta and lowest expression in the amnion. LOXL2 expression differs in that it is 
detected predominantly in chorionic cytotrophoblasts of the membranes with only low 
expression levels in the amnion and placenta (168, 187, 188). 
Lysyl oxidase-like protein 3 (LOXL3) 
LOXL3 was detected as an osteoblast-derived EST and later in other tissue 
panels (171). LOXL3 mRNA encodes a predicted mass of 80.3 kDa protein with a 
putative signal peptide in the N-terminus. The nonprocessed LOXL3 polypeptide shared 
a 55% amino acid sequence similarity with the LOXL2 polypeptide and the C-terminal 
residues showed a high degree similarity with the LOX, LOXL and LOXL2 polypeptides, 
51%, 53% and 69% respectively.  The N-terminal region of the LOXL3 polypeptide 
contains a bipartite nuclear localization signal (KKQQQSKPQGEARVRLKG), which is 
not found in any other LOX isozyme. Despite the presence of the nuclear localization 
signal, there was no evidence to show any role of LOXL3 in the nucleus, which has been 
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shown to be due in part to the LOX polypeptide (112) or LOXL (189). LOXL3 gene has 
been mapped to chromosome 2p13 in humans (170) and chromosome 6 in mice (171, 
172). LOXL3 is expressed highly in placenta, heart, ovary, testis, small intestine and 
spleen (162, 171).  
Lysyl oxidase-like protein 4 (LOXL4) 
LOXL4 was cloned from placental, kidney, fetal tissues and chondroblast and 
osteoblast cDNA (173-175). The deduced 756-amino acid protein contains an N-terminal 
signal sequence, 4 scavenger receptor cysteine-rich (SRCR) domains, lysyl and tyrosyl 
residues that form the carbonyl cofactor within the catalytic site, and a cytokine receptor-
like domain at the C terminus. LOXL4 shares 51% and 54% amino acid identity with 
LOXL2 and LOXL3, respectively. LOXL4 gene has been mapped to chromosome 10q24 
in humans (175) and chromosome 19 in mice (162, 173). LOXL4 is highly expressed in 
skeletal muscle, testis and pancreas and not expressed in leukocytes (173).  
Novel biological functions of LOX 
LOX in tumor suppression 
LOX was reported to show tumor suppression in 1990 (190). A cDNA species 
named as ras recision gene (rrg) was identified when mouse NIH 3T3 cells were 
transformed with LTR-c-H-ras. This DNA was markedly down-regulated and restored 
when the transformed cell line (RS485) was treated with interferon to obtain a persistent 
revertant cell line (PR4). The revertant cells are phenotypically non-transformed and 
non-tumorigenic. Once an rrg antisense RNA was transfected into PR4 cells, the 
reappearance of the tumorigenic and transformed phenotype was observed. 
Subcutaneous administration on these antisense cells into athymic mice induced tumor 
formation. The cDNA sequences of the mouse rrg and rat Lox were subsequently found 
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to be identical, indicating that rrg encodes Lox (191), the activity of which was already 
known to be markedly low in the medium of malignantly transformed cultured human cell 
lines (192). Expression of LOX was down-regulated in immortalized rat 208F fibroblasts 
after transformation by activated H-ras (193, 194) and up-regulated in spontaneous 
phenotype revertants that continued to express the ras oncogene (193). In spontaneous 
phenotypic revertant, LOX expression was found to be irreversibly and coordinately 
regulated with type I collagen expression (193). A tumor suppressor role of LOX was 
demonstrated by stable transfection of a LOX cDNA in antisense orientation to normal 
rat kidney fibroblasts (NRK-49F). The transfected cells exhibited a loose attachment to 
plate, anchorage-independent growth, and high tumorigenicity in nude mice, and also 
showed an impaired response of the PDGF and IGF-1 receptors to their ligands (195).  
Several malignant transformed human cell lines showed low level of LOX mRNA and 
enzyme activity (196). The LOX gene was identified as a target for the anti-oncogenic 
transcription factor (IRF-1), which manifests tumor suppressor activity and contributes to 
the development of human hematopoietic malignancies (197). In malignant human 
breast carcinomas, LOX was highly expressed in myofibroblasts and myoepithelial cells 
surrounding the in situ tumor and in the reactive fibrosis facing the invasion front of 
infiltrating tumors (198) and type I, III and IV collagens and elastin were found to be co-
distributed with LOX resulting in the formation of a scar-like peritumor barrier (198). In 
contrast, LOX was found to be absent from the carcinoma cells suggesting a possible 
host defense mechanism for cancer. Interestingly a late stromal reaction lacking of LOX 
favors tumor dispersion (198). In mouse prostate cancer model, LOX was expressed in 
normal epithelium, but lost in primary prostate cancer and associated metastatic lesions 
(199). In broncho-pulmonary carcinoma, a strong expression of LOX is associated with 
the hypertrophic scar-like stromal reaction found at the front of tumor progression. In 
contrast, little or no expression was found within the stromal reaction of invasion 
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carcinomas, small cell carcinomas and neuro-endocrine carcinoma (200). It has been 
demonstrated that a loss or reduction of LOX function during tumor development may be 
a direct consequence of somatic mutations and may be associated with the 
pathogenesis of colon cancer (201). The LOX gene is located in chromosome region 
5q23, which is known to be deleted in a high frequency in many different types of cancer 
(202). LOX was reported to inhibit ras-mediated transformation by preventing the 
activation of NF-Kappa B (NF-B) (203). Lysyl oxidase propeptide (LOPP) was also 
reported to have tumor suppression ability by inhibiting Erk1/2 Map kinase activation (86, 
204) and recently by inhibiting Akt activity and BCL2, a tissue-specific NF-B target gene 
(205).   
LOX dependent chemotaxis 
ßAPN has been reported to inhibit fibroblast migration in a dose-dependent 
fashion without inhibiting proliferation (206). Purified 32 kDa mature LOX was shown to 
play a role as a potent chemoattractant for human peripheral blood mononuclear cells, 
with a 237% increase in migration over the enzyme-free or catalytically inhibited LOX 
controls seen at 10-9 M LOX (207). The result showed that H2O2 product of the LOX-
catalytic reaction appeared to mediate the chemotactic response since the observed 
result was not detected when the LOX was inactivated or absent from the reaction (208). 
The result also suggested that the chemotactic effect was not due to the reaction of LOX 
with secreted protein in the media but more likely due to the direct access of LOX to cell-
associated substrates. The cellular responses after addition of LOX showed elevated 
level of intracellular H2O2, enhanced stress fiber formation, and increased focal adhesion 
assembly, consistent with the induction of chemotactic response. The chemotactic 
response was prevented by the prior addition of catalase, indicating the crucial role of 
the H2O2 product of the LOX-catalytic reaction (208). In breast cancer studies, LOX and 
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its isoform mRNA levels are upregulated in invasive type compared to those of non-
invasive type and the invasion phenotype was facilitated by active but not inactive LOX. 
In addition, the invasion was inhibited when the antisense mRNA of LOX was 
transfected or ßAPN was added into the cultured (209). A further report from the same 
group demonstrated that this LOX-dependent chemotactic response of breast cancer 
cells was elicited by the H2O2 product of the LOX-catalytic reaction on unidentified 
substrates (210). Recently it has been shown that actin stress fiber formation and Rho 
activity in breast cancer cell line are increased through the p130 (Cas)/Crk/DOCK180 
signaling complex by inhibition of LOX in these cells (211). It suggests that the down-
regulation of LOX activity could limit the invasiveness of breast cancer. Other isozymes 
have been reported that their expression are high in metastatic breast cancer cells and 
correlate with increased tumor malignancy and increased fibrotic foci (209, 212). The 
elevation of LOX under hypoxic condition in head and neck tumor cells appeared to be 
essential for the hypoxia-induced metastatic response of these cells and the increased 
invasiveness was prevented by treatment of ßAPN, LOX antisense oligonucleotides, 
LOX antibody or short hairpin RNA expression but not with LOX sense oligonucleotides 
(135). This study did not show the role of H2O2 product of the LOX-catalytic reaction. 
Another study showed that LOX interacts with hormone placental lactogen and 
synergistically promotes breast epithelial cell proliferation and migration. However, the 
study showed that lactogen was neither a substrate nor an inhibitor so the H2O2 from the 
oxidative reaction was not generated but their coexpression resulted in a 240% increase 
in cell migration (213). Recently, LOX has been reported to be correlated with focal 
adhesion kinase (FAK)/paxillin activation and migration in invasive astrocytes. Tyrosine 
phosphorylation of FAK/paxillin was inhibited by ßAPN treatment and catalase addition 
(214).  
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Intracellular and intranuclear activities 
LOX was reported to be associated with cytoskeleton protein in cytoplasm in 
cultured fibroblasts (215). It was not conclusive that the observed LOX represented the 
proenzyme and/or mature LOX since the molecular weight of the LOX was not 
determined. It has been reported that an intracellularly expressed recombinant mature 
32 kDa LOX might regulate the activity of COL3A1 gene promoter (195). The coinjection 
of LOX with oncogenic p21-rasval12 into Xenopus laevis oocytes suggests one possible 
intracellular role for LOX in antagonizing a Ras-induced meiotic maturation of these 
cells. It has been suggested that a LOX-dependent block in oocyte maturation may be 
downstream of Erk2, a member of the mitogen-activated protein kinases (216). 
A mature LOX 32kDa was observed by immunocytochemistry and Western blot 
analysis in the nucleus of rat vascular smooth muscle cells and 3T3 fibroblast (112). In 
addition, the nucleus of the vascular smooth muscle cells contained lysinonorleucine 
(LNL), which is the adduct formed during cross-linking formation of LOX and the 
formation of LNL was prevented by administration of ßAPN, confirming a role of LOX in 
the reaction (112). It was demonstrated that a purified bovine 32 kDa LOX polypeptide 
fluorescent-labeled with rhodamine was able to enter into the cytosol and become 
rapidly concentrated into the nuclei of cultured smooth muscle cells. The intracellular 
uptake and distribution of intranuclear LOX were not altered by ßAPN showing its 
independency from the amine oxidase activity of LOX (217). The intracellular LOX was 
reported to activate the transcription activity of human collagene III promoter via possible 
involvement of Ku antigen (218). LOX has been reported to locate in cytoplasm of 
MDCK II kidney cells and MCF-10A breast cancer cells however, the lysyl oxidase 
activity from the cell lysate could not be detected (189). Another report from a different 
group showed a stage-dependent intracellular distribution of mature LOX 32kDa and 
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LOPP 18kDa in osteoblasts. In proliferating cells, mature LOX located in nucleus and 
perinuclear region while LOPP associated with Golgi and endoplasmic reticulum. In 
differentiating cells, mature LOX and LOPP colocalized with the microtubule network 
(113). However, the mechanism of how LOX and LOPP can be uptaken intracellularly or 
intranuclearly remains unelucidated (112). Recently LOX has been reported to regulate 
elastin promoter via intracellular effects of transforming growth factor-ß1 (TGF-ß1). The 
author showed the reduction of Smad 3 and 4 in the addition of TGF-ß1 when the coding 
sequence of mature LOX without signal peptides was transfected in 293T cells. The 
cross control mechanism remains unclear (219). 
Growth factor and cellular modulation 
In addition to collagen and elastin, purified LOX oxidized a number of basic 
globular proteins in vitro with pI values > 8.0, but did not oxidize neutral or acidic globular 
proteins with pI value < 8.0 (126). The study demonstrated Histone H1 as a substrate of 
LOX by detecting the increase of lysinonorleucine cross-link and ACP in histone H1 
sample after incubation with purified LOX. Histones are involved in chromatin packing in 
nucleus and can be oxidized by LOX. The histone oxidation might modulate the packing 
state of nuclear chromatin (220). Basic fibroblast growth factor (bFGF) was reported to 
be a substrate of LOX in vitro. The oxidation of lysine residues in bFGF by LOX resulted 
in the covalent cross-linking of bFGF monomers to form dimers and higher order 
oligomers. The fluorescence LOX assay showed temperature dependent of amine 
oxidase activity of LOX in which LOX oxidized 14 lysine residues at 55C, and 5-6 
residues at 37C. The biological effect of LOX oxidized bFGF resulted in the inhibition of 
bFGF nuclear localization, and the inhibited FGF-2 mediated cell cycling, resulting in cell 
growth suppression (134).  
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Lysyl oxidases in an osteoblast cell culture systems and in mineralized tissues 
LOX was first identified in bone from saline extract in 1968 (50). Several reports 
have shown that the activity of purified bone LOX was inhibited by ßAPN but it was not 
well characterized (50, 90). LOX was also identified in dentin (221). In chick calvarial 
osteoblast cultures, once treated with 20 g/ml ßAPN, total collagen synthesis was 
increased two folds with no change in mRNA levels for collagen type I but the 
accumulated collagen in matrix was decreased by 50% and mineral deposit was 
reduced compared to control. The ßAPN treated cultures showed a wider diversity of 
fibril diameters with a larger average collagen fibril diameter compared to control (222). 
This study implicated the role of collagen cross-link in the collagen deposition, 
fibrillogenesis and fibril stability. In 3-dimensional cultures of chondrocytes, treated with 
0.25 nmM ßAPN, collagen type II synthesis significantly increased and collagen fibril 
diameters were larger compared to controls. In addition, the expression of other minor 
collagens, collagen type XI, and aggrecan increased significantly in the presence of 
ßAPN (223). A study of LOX expression and activity in osteosarcoma cell line showed 
that LOX activity was not related closely to LOX mRNA  levels among the different cell 
clones and the activity of LOX was BMP-1 dependent (224). The role of LOX in 
controlling insoluble collagen deposition in MC3T3-E1 (MC) osteoblastic cells has been 
also studied and reported that the maximum increase in LOX activity precedes the most 
efficient phase of insoluble collagen deposition. Once treated with 400 M ßAPN, the 
cultures showed a 44% increase of insoluble collagen deposition compared to control 
cultures. In addition, the collagen fibril diameter showed irregular shapes and a larger 
average diameter (30%) compared to the control cultures. The authors suggested that 
the increase of collagen accumulation in the matrix was due to insufficient proteolytic 
activity to destroy abnormal collagen fibrils (73). The administration of PCP inhibitor 
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diminished collagen processing and LOX activity; however, the collagen cross-links, Pyr 
and d-Pyr were not altered. Moreover, a slight increase (10%) of collagen fibril diameter 
was reported (225). LOX has been also shown to be regulated by bFGF (226), TGF-ß1 
(75) and TNF-α (79) in MC3T3-E1 (MC) cells. The expression of LOX and its isoforms in 
MC cells have recently been investigated and the result showed that LOX and all LOXLs 
except LOXL2 were expressed in this cell line and the expression during the cell 
differentiation and matrix mineralization was distinct from one another (74). The stage-
dependent intracellular distribution of mature LOX 32kDa and LOPP 18kDa was 
investigated in MC cells. In proliferating cells, mature LOX located in nucleus and 
perinuclear region while LOPP associated with Golgi and endoplasmic reticulum. In 
differentiating cells, mature LOX and LOPP colocalized with the microtubule network 
(113). 
Osteolathyrism  
Osteolathyrism is caused by chronic ingestion of the sweet pea Lathyrus 
odoratus, which contains -(-glutamyl)aminopropionitrile, a potent irreversible inhibitor 
of LOX when metabolized to ßAPN (115, 227). Other inhibitors are ureides, 
semicarbazide and thiosemicarbazide, which are believed to chelate the prosthetic Cu-
(II)-bipyridine cofactor complex in LOX (228). LOX inhibition leads to the diminished 
cross-linking of collagen and elastin and consequently causes weakness and fragility of 
connective tissue (i.e., skin, bones, and blood vessels [angiolathyrism]) and the paralysis 
of the lower extremities associated with neurolathyrism. A study in Bangladesh showed 
that the prevalence of neurolathyrism among neurological patients is 0.14% and the 
prevalence was higher among young males. The patients always consumed green 
shoots of Lathyrus sativus (229). The prevalence of osteolathyrism in neurolathyritic 
patients was about 12% (230). The connective tissue manifestations include 
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kyphoscoliosis, bone deformities, weakening of tendons and ligament attachments, 
dislocation of joints, weakening of skin and cartilage, hernias and dissecting or saccular 
aneurysm of the aorta (231). In a rabbit model, osteolathyrism does not become 
manifest until practically all mature cross-linking that can be affected has been inhibited 
(232). In experimental osteolathyritic rat model, osteolathyrogens cause a spectrum of 
tissue alterations in skeleton, soft connective tissue and arteries (233). Ectopic 
exostoses and aneurysmal-like bone cysts in mandible and long bones were observed 
(234, 235) due to significantly impaired turnover and remodeling rates of periosteal and 
endosteal bone (236). Fracture healing in osteolathyritic animals results in excessive 
callus formation. The vast fracture callus is very fragile and consists of irregular cartilage 
and premature woven bone (237, 238). Fractured tibias in the animal developed 
excessive amounts of mechanically weak callus tissue with irregular cartilage and  
showed reduced glycosaminoglycan accumulation. In lathyritic calluses, the maximal 
mRNA of type II and IX collagens and aggrecan core protein was peaked 4 days earlier 
than in controls reflecting the less well control of endochondral ossification in lathyritic 
calluses. Interestingly the expression of TGF-ß1 mRNA in lathyritic calluses was already 
peaked at the early time-points while that of control was relatively low and increased 
gradually at later time-points of study (239). 
TGF-ß in bone and its potential regulation by LOX 
TGF-ß is one of the most potent pleiotropic growth factors controlling a diverse 
set of cellular processes, e.g. cell growth, differentiation, migration, apoptosis, and 
synthesis of ECM proteins including collagen (240-245). The TGF-ß superfamily 
comprises over 35 structurally related polypeptides in vertebrates including TGF-ßs, 
activins, nodal, bone morphogenetic proteins (BMPs) and some other related proteins, 
and those have crucial roles in development and in tissue homeostasis (246). All of 
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these members share a cluster of conserved cysteine residues forming a characteristic 
cysteine knot. They are synthesized as precursors with a large N-terminal propeptides 
that is proteolytically cleaved from a mature C-terminal domain peptide. 
TGF-ß1 is the prototypic member of the TGF-ß superfamily, and bone ECM is a 
major storage site in the body for this growth factor (247). Though TGF-ß2 and 3 are 
also present in bone, TGF-ß1 is the predominant isoform (>90%) at the level of 200-700 
μg/Kg in this tissue (248, 249). In bone, TGF-ß1 plays pivotal roles in many, if not all, 
aspects of the tissue development, remodeling, mechanical properties and aging (250-
252). Numerous studies, though not always consistent, have shown that TGF-ß1 
stimulates recruitment and proliferation of osteoblast progenitors (253, 254), stimulates 
matrix production such as collagen, fibronectin, osteopontin, osteonectin, proteoglycans, 
but inhibits osteocalcin (250, 255), inhibits late stage of osteoblast differentiation and 
matrix mineralization (256, 257), and modulates osteoclast differentiation (258). The 
abundance of this growth factor with such potent effects on cells predicts the need for 
tight regulation of its biological activities. Indeed, several studies have shown that 
deregulation/overactivation of TGF-ß could be detrimental to osteoblastogenesis and 
bone formation causing bone defects (259-261).   
TGF-ß1 is secreted as a latent complex that needs to be activated before being 
capable of eliciting biological effects (262, 263), and it appears that it is the only growth 
factor known to be produced in a latent/inactive form. The latency is achieved by 
noncovalent association between TGF-ß and its propeptide, called latency-associated 
peptide (LAP), forming a ~100 kDa small latent complex (SLC). For this association, 
thus, to confer “latency” to TGF-ß, res 50-85 near the N-terminus of LAP is important 
(264). More recently, it has been reported that the LSKL sequence (res 54-57) in this 
region of LAP is critical for its association with mature TGF-ß (265). In the same report, 
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the authors also identified the RKPK sequence near the C-terminus of mature TGF-ß as 
a potential recognition sequence for LSKL. Interestingly, the C-terminus of the mature 
TGF-ß (res 83-112) including the RKPK sequence has also been demonstrated to be the 
critical site for the binding to its type II receptor (TßRII) that initiates the signaling 
cascade of TGF-ß (241, 266, 267). Thus, the association of LSKL of LAP and RKPK of 
TGF-ß may sterically prevent receptor binding (265). It is of interest to note that the 
vicinity of the critical regions of LAP and TGF-ß for their association and the region of 
TGF-ß to bind TßRII for signaling are enriched in basic amino acids, including several 
Lys residues, yielding high pI values (e.g. estimated pI for res 50-85 of LAP is 9.98, and 
for res 83-112 of mature TGF-ß1 is 9.24). In many cell types, LAP is further disulfide-
bonded by latent TGF-ß binding proteins (LTBPs) to form a ~290kDa large latent 
complex (LLC) prior to secretion, and in the ECM, LLC is stored possibly by covalently 
linked to matrix components (263, 268). LTBP is thought to be important for efficient 
secretion, storage of TGF-ß in ECM and TGF-ß activation (268). Although almost all 
nonmalignant cells secrete TGF-ß as a part of LLC, bone cells form an exception as they 
efficiently secrete SLC, thus, lacking LTBP (269-271). At least 50% of the latent TGF-ß 
forms produced by bone cells was found to be SLC (272) indicating its specific role in 
bone biology. Bone cells also produce LLC like other cell types (273) where LTBP may 
play dual roles in matrix storage and structural element for bone formation (272). The 
latent TGF-ß can be activated by plasmin, thrombospondin-1, αvß 6 integrin, heat, low 
pH, etc. (263). Such low pH can be generated by osteoclasts during bone resorption to 
activate TGF-ß (7, 274). Since bone is a dynamic, constantly remodeling tissue, tight 
regulation of TGF-ß activity (either in a free or a complex form) is crucial. The regulation 
can be done by: 1. stable TGF-ß binding molecules limiting the bioavailability of this 
growth factor during remodeling, and/or 2. TGF-ß modifications that reduces its potency 
as a growth factor or stabilizes its latency. In bone matrix, there are several TGF-ß 
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binding molecules including small leucine-rich proteoglycans, decorin and biglycan (260, 
275, 276) that may sequester TGF-ß in the matrix and/or diminish TGF-ß binding to its 
cell receptor (277). However, the significance of these interactions in bone ECM is not 
known. Furthermore, potential extracellular modification of TGF-ß that may change 
and/or stabilize the potency is unknown. 
During the course of my study on the biological significance of the post-
translational modifications of collagen in bone, I discovered that in an osteoblastic cell 
culture system, higher LOX expression resulted in less collagen production and 
suppressed TGF-ß1 signaling while lower LOX expression exhibited more collagen 
production and enhanced TGF-ß1 signaling. This intriguing finding prompted me to 
examine the potential interaction between LOX and this growth factor. When these two 
proteins were co-expressed in 293 cells, the binding was detected in a dose-dependent 
manner. No binding was identified between LOX and BMPs tested or LAP. Furthermore, 
TGF-ß1 was found to be bound LOX in the mineralized bone matrix. Considering the 
facts that LOX possesses a strong preference towards basic proteins as its substrates 
and TGF-ß1 (and LAP) is a basic protein, especially its critical domain for “latency” and 
“signal transduction” is enriched in basic amino acids including Lys residues, it is then 
possible that LOX may bind and oxidize TGF-ß1 in bone. This may result in limiting 
bioavailability and activity of this growth factor.  
CHAPTER II 
 
Hypothesis 
 Lysyl oxidase regulates TGF-ß1 function in bone via its amine oxidase activity. 
 
 
CHAPTER III 
 
STUDY I 
Lysyl oxidase regulates collagen quality and quantity in osteoblasts 
Phimon Atsawasuwan, Yoshiyuki Mochida, Michitsuna Katafuchi, Mitsuo Yamauchi 
 
 
Specific aims 
1. To establish several MC cell clones that express higher or lower levels of LOX by 
overexpression or antisense approaches.  
2. To characterize collagen cross-linking, production, fibrilogenesis and matrix 
mineralization in the clones. 
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ABSTRACT 
Fibrillar type I collagen controls spatial aspects of mineralization by providing a 
stable template in most mineralized tissues. The stability of the fibril is primarily derived 
from covalent intermolecular cross-linking initiated by lysyl oxidase (LOX). In this study, 
MC cell-derived clones expressing higher (S) or lower (AS) levels of LOX were 
generated, and the effects on collagen production, fibrillogenesis and mineralization 
were characterized in vitro. In comparison to controls (parental MC3T3-E1 cells (MC) 
and empty vector (EV) clones), the S clones showed significant decreases in total 
collagen production and increases in pyridinoline cross-link and total aldehydes, AS 
clones showed the opposite phenotypes. The numbers and diameter of collagen fibrils of 
S clones were markedly less and smaller while the diameter of fibrils of AS clones were 
larger than those of controls. The onset of mineralization was delayed in both S and AS 
clones in comparison with the controls indicating defective matrix mineralization. 
CONCLUSION: These results indicate that LOX is critical in regulating not only quality 
but quantity of collagen and mineralization in an osteoblastic cell culture system.
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INTRODUCTION 
Mineralization is a multifactorial process orchestrated by cells and a number of 
matrix molecules. In bone, fibrillar type I collagen regulates spatial aspects of 
mineralization by providing a 3-dimensional template for minerals to deposit and grow. 
One of the characteristics of collagen is its large number of post-translational 
modifications, many of which are unique to collagens (15, 35) Covalent intermolecular 
cross-linking is the final modification essential for the stability of the fibrils, thus, for the 
functional fibrils. The stability and adaptability of the fibril attained by specific covalent 
intermolecular cross-linking seem to be essential and the alterations of collagen cross-
linking were indeed observed in numerous bone disorders (38, 278, 279).The process of 
collagen cross-linking is initiated by the conversion of telopeptidyl lysine and 
hydroxylysine residues to aldehyde through the action of an enzyme, lysyl oxidase (EC 
1.4.3.13, protein-lysine 6-oxidases, LOX) (15, 34). The aldehyde produced then 
undergoes a series of condensation reactions to form intra- and intermolecular cross-
links that are essential for the stability of collagen fibrils (15). A study of LOX in 
MC3T3E-1 (MC) cells showed that the maximum increase in lysyl oxidase activity 
precedes the most efficient phase of insoluble collagen deposition. Once treated with 
400M ßAPN, the cultures showed a 44% increase of insoluble collagen deposition 
compared to control cultures. In addition, the collagen fibril diameter showed irregular 
shapes and a higher average diameter (30%) compared to the control cultures (73). 
Recently we have reported that LOX and all LOXLs, except LOXL2, were expressed in 
MC cells, a osteoblastic cell line, and that the expression pattern during cell 
differentiation and matrix mineralization was distinct from one another (74). The 
expression of LOX mRNA is the highest form among its family and the expression 
pattern corresponds to that of type I collagen in this cell line. To obtain further insights 
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into the function of this enzyme in osteoblastic cells, we generated several MC cells-
derived clones that express higher or lower levels of LOX and investigated the effects on 
collagen matrix in their respective cultures. Here we have demonstrated that LOX has 
significant effects on collagen fibrillogenesis and mineralization in vitro. 
 41 
EXPERIMENTAL PROCEDURES 
Cell Lines and Culture Conditions– MC cells subclone 4, (280) were purchased 
from American Type Culture Collection (CRL-2593) and maintained in -minimum 
essential medium (Gibco) containing 10% FBS (Atlanta Biologicals) and supplemented 
with 100 U/ml penicillin G sodium (Gibco), 100 g/ml streptomycin sulfate (Gibco) in a 
5% CO2 atmosphere at 37 C. The medium was changed twice a week. 
Isolation of LOX cDNA and generation of constructs– Total RNA was isolated 
from MC cells using TRIzol reagent (Invitrogen) according to the manufacturer’s 
protocol. Two g of total RNA was used for reverse transcription and the cDNA was 
synthesized using the Omniscript Reverse Transcriptase kit (Qiagen). Specific primers 
for the coding region of the mouse LOX (Genbank accession NM010728) was as 
follows; forward primer, 5’-CCCGGTCTTCCTTTTTCTCCTAGCC-3’ and reverse primer, 
5’-ATACGGTGAAATTGTGCAGCCTGA-3’. PCR amplification was performed by 
ProofStart DNA polymerase (Qiagen) with an annealing temperature of 62 C for 35 
cycles. After adding 3’A-overhangs, the PCR products were then ligated into the 
pcDNA3.1/V5-His-TOPO mammalian expression vector (Invitrogen) generating the 
plasmid containing LOX (pcDNA3.1/V5-His/LOX) construct. The orientation and 
molecular weight of the ligated insert were analyzed by HindIII (Roche) restriction 
enzyme digestion followed by 1.2% agarose gel electrophoresis. Plasmids containing 
digested inserted of the 996 bp, i.e. in a sense (S) or 343 bp, i.e. antisense orientation 
(AS) orientation were sequenced at the UNC-CH DNA sequencing facility (University of 
North Carolina, Chapel Hill, NC). A search in the database confirmed that the ligated 
PCR product was 100% identical to the mouse LOX sequence from Genbank. 
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Transfection and generation of stable cell clones– MC cells were transfected with 
pcDNA3.1/V5-His/LOX constructs (S and AS orientation) or pcDNA 3.1/V5-His A vector 
(empty vector [EV]; Invitrogen) using Fugene 6 transfection reagent (Roche). After 48 h, 
cells were trypsinized and plated at a low density.  Single cell-derived clones (S and AS 
clones) were isolated and maintained in the presence of 400 g/ml G418 (Invitrogen) for 
up to 4 weeks.  
Immunoprecipitation and Western blot analysis of the S and AS clones– MC, EV, 
S and AS clones were plated onto 10-cm dishes (Falcon) at a density of 2.0 x105/dish 
and cultured in -minimum essential medium (-MEM, Gibco containing 10% FBS) with 
the same supplements described above. After 7 days of cell culture, culture media were 
collected and incubated with anti-LOX antibody (Imgenex) at 4 C overnight. After the 
addition of rec-Protein G-Sepharose conjugate beads (Zymed laboratories) and 
incubation at 4C for 30 min, the samples were washed with lysis buffer containing 
150mM NaCl, 20 mM Tris-HCl pH 7.5, 10mM EDTA, 1% Triton X-100, 1% deoxycholate, 
1.5% aprotinin, and 1mM phenymethylsulfonyl fluoride three times. Protein bound to the 
beads were dissolved in SDS sample buffer (100mM Tris HCl, pH 8.8, 0.01% 
bromophenol blue, 36% glycerol, and 4% SDS) in the presence of 10mM dithiothreitol 
(DTT), applied to 4-12% gradient SDS-PAGE (Invitrogen), transferred onto a 
polyvinylidene fluoride membrane (Immobilon-P, Millipore Corp.), and subjected to 
Western blot analysis with anti LOX antibody and a secondary antibody, an anti-rabbit 
IgG conjugated to alkaline phosphatase [(ALP), Pierce Biotechnology]. The 
immunoreactivity was visualized by an ALP conjugate substrate kit (Bio-Rad 
Laboratories). 
Proliferation assay– MC, EV, S and AS clones were plated in triplicate at a 
density of 5x104 cells /ml in a 96-well plate, and cultured with -MEM and 10% FBS. At 
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day 2, 4 and 6 days of cell culture, the cells were subjected to MTS cell proliferation 
assay (CellTier 96®, Promega) according to the manufacturer’s protocol. Briefly, 100 l 
of MTS solution was added into each well and incubated at 37 C for 4 hrs. The amounts 
of formazan compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium), MTS, produced by metabolically active cells were 
measured by absorbance at 490 nm. 
Quantitative Collagen Cross-link Analysis– MC, EV, S and AS clones were 
cultured in -MEM, 10% FBS and 50g/ml ascorbic acid. After 2 weeks of culture, 
cells/matrices were washed with phosphate buffered saline (PBS), scraped into a 1.8 ml 
eppendorf tube and washed with PBS, distilled deionized water (DDW) twice then 
lyophilized. Two milligrams of the lyophilized samples were suspended in 0.15M N-
trismethyl-2-aminoethanesulfonic acid and 0.05M Tris-HCl buffer (pH 7.4) and reduced 
with standardized NaB3H4 (281), hydrolyzed with 6 N HCl in vacuo, after flushing with N2 
at 105C for 22 h. The hydrolysates were dried by a speed vacuum concentrator (Savant 
Instruments Inc), dissolved in 300 µl of DDW and filtered through a 0.22 µm membrane 
(Costar, Corning Inc) and kept in 4C. Aliquots were subjected to amino acid analysis to 
determine Hyp and the hydrolysates with known amounts of Hyp were analyzed for 
cross-links on a cation-exchange column (AA-991; Transgenomic) linked to a 
fluorescence detector (FP1520; Jasco Spectroscopic) and a liquid scintillation analyzer 
(500TR series; Packard Instrument) as reported previously (282). All reducible cross-
links and aldehydes were measured as their reduced forms. The major reducible cross-
links, dihydroxylysinonorleucine and hydroxylysinonorleucine (DHLNL, HLNL) and 
precursor aldehydes and non-reducible cross-links, pyridinoline and deoxypyridinoline 
(Pyr, d-Pyr) were simultaneously quantified by the cross-link analyzer. The quantities of 
the collagen cross-links were expressed as moles/mole of collagen (283). The analyses 
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were done in triplicate and the values are means+SD. To confirm the reproducibility of 
the results, three independent experiments were performed. 
Collagen content determination– MC, EV, S and AS clones were cultured as 
described above. At day 3 and 7, cell culture medium were collected and cell/matrix 
layers were collected and lyophilized as described above. The dry cells/matrices and 
lyophilized medium were hydrolyzed with 300 µl of 6 N HCl (Pierce) in vacuo, after 
flushing with N2, for 22 h at 105ºC, dried, dissolved in 300 l of distilled water, filtered 
with 0.22 m filter unit and kept in 4C. An aliquot of each hydrolysate was subjected to 
amino acid analysis on a Varian high-performance liquid chromatography (HPLC) 
system (9050/9012; Varian Associates Inc) using ninhydrin (Pickering laboratories) for 
color development at 135oC to determine hydroxyproline residue (282). The collagen 
content in the cells/matrices was calculated using a value of 300 residues of Hyp per 
collagen molecule. The total collagen content in the medium and matrices was 
calculated and normalized with the number of the cells in each dish. To confirm the 
reproducibility of the results, three independent experiments were performed. 
Transmission electron microscopy– The cell/matrix layers of MC, EV, S and AS 
clones at week 3 of study were washed with PBS, fixed with 3% glutaraldehyde and 1% 
tannic acid in 0.1 M cacodylate buffer, pH 7.4 for 90 mins. The specimens were then 
post-fixed in 1% osmium tetroxide in 0.1M sodium cacodylate, pH 7.4 for 1 hour at room 
temperature. The samples were dehydrated with ethanol, embedded in Polybed 812 
epoxy resin (Polysciences) and ultrathin sectioned at 70 nm with a diamond knife.  The 
sections were stained with 4% aqueous uranyl acetate for 20 min, followed by Reynolds 
lead citrate for 8 min. The sections were observed at 80 kV using a Leo EM 910 
transmission electron microscope (LEO Electron Microscopy). Digital images were 
acquired at 40,000X magnification using a Gatan Bioscan CCD camera and Digital 
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Micrograph software (Gatan, Inc).  For each sample, a total of 500 collagen fibril 
diameters and the number of fibrils per m2 were measured randomly using Scion Image 
software (Scion Corporation). 
In vitro mineralization assay– MC, EV, S and AS clones were plated on 35 mm 
plastic dishes at the density of 2x105 cells/dish (Falcon) and cultured until confluence.  
The medium was then replaced with the one supplemented with 50 g/ml of ascorbic 
acid and 2 mM of ß-glycerophosphate (mineralization medium), and maintained for up to 
4 weeks.  In vitro mineralization assay was performed at the end of week 2 and 4.  At 
each time point, cell/matrix layers were washed with 1X PBS twice, fixed with 100% cold 
methanol, stained with 1% Alizarin Red S (Sigma) for 15 min and washed with DDW and 
dried at room temperature(74). At week 4, the calcium contents were quantified by 
measuring the amount of Alizarin red S bound to mineralization nodules in the cultures. 
Briefly, after staining with Alizarin red S, the cultures were washed with 10% (w/v) 
cetylpyridinum chloride in 10 mM sodium phosphate, pH 7.0 for 15 min. The dye 
concentration in the extracts were subjected to spectrophotometer at absorbance 562 
nm (284, 285) to compare the amount of alizarin and normalized with cell numbers. To 
confirm the reproducibility of the results, three independent experiments were 
performed. 
Statistical analyses– All statistical analyses were performed using Sigma stat 
software. Data are expressed as mean+SD. Statistical differences were determined by 
one-way ANOVA followed by a Tukey-Kramer multiple comparison test at P=0.05. 
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RESULTS 
Generation of the S and AS clones– The immunoprecipitation/Western blot 
analysis of three S, three AS clones and the controls are shown in Figure 2.1. S3 
showed the highest level of LOX (S3: 2.34, S2: 2.25 and S1: 1.47 fold) while AS1 
showed the lowest level of LOX (AS1: 0.49, AS2: 0.73, AS3: 0.85 fold) compared to the 
average expression level of MC and EV. Using MTS assay, the proliferation rate of S 
clones were comparable with controls (MC and EV) while those of AS clones were 
slightly lower compared to controls at the same timepoint of study but there is no 
statistically difference among the clones and when compared to controls (P>0.05) 
(Figure 2.2). 
Quantitative collagen cross-link analysis–To confirm if the generated S and AS 
clones secreted functional recombinant LOX, the collagen cross-links in each clones 
were quantified. The collagen cross-links produced in MC, EV, S, and AS clones at 2 
weeks of culture were bifunctional reducible cross-links, i.e. DHLNL and HLNL and a 
trivalent nonreducible cross-link, Pyr. The cross-link analysis of S clone exhibited higher 
levels of total aldehydes (DHLNL+HLNL+2xPyr), DHLNL and Pyr whereas that of AS 
exhibited lower levels of total aldehydes, DHLNL and Pyr (Figure 2.3). The Pyr contents 
in S clones were constantly higher (157, 206 and 260 % increase) whereas those in AS 
clones lower (64, 57and 42% decrease) than those of controls (P<0.05) (Table 2.1). The 
data from cross-link analysis is consistent with the level of LOX in S and AS clones 
(Figure 2.1).  
Collagen content determination– The total collagen content in each clone at day 
3 and 7 of the study was shown in Figure 2.4. After normalized with cell numbers in each 
dish, the results demonstrated that the total collagen content (in medium and matrix) in 
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all S clones was significantly lower than those of controls (MC and EV) at both time-point 
of study (P<0.05) while that in all AS clones was comparable to those of the controls at 
day 3 but significantly higher than those of controls at day 7 in AS1 and AS2 clones 
(P<0.05).  
Ultrastructural analysis of collagen fibrils– Cross-sectional views of collagen 
fibrils obtained from cultures of S (S1, S2, S3) and AS (AS1, AS2, AS3) clones and the 
controls (MC, EV) are shown in Figure 2.5. As shown in histogram, MC cells had a mean 
diameter of 46.2+9.4 nm with a range of 29.2-87.5 nm, which is similar to that of the EV 
clone (mean 42.3+6.8 nm; range 29.2-62.5 nm). In all S clones, the mean fibril diameters 
and their range were significantly smaller than those of controls (P<0.05). Among the S 
clones, S3 that exhibited the highest level of LOX overexpression (Fig 2.1) showed the 
smallest fibril diameter (mean 21.1+7.9 nm; range 3.7-46.6 nm) followed by S2 clones 
(mean 24.2+9.97 nm; range 3.7-44.1 nm) and S1 clones that exhibited the lowest level 
of LOX overexpression (mean 30.1+4.4 nm; range 3.7-44.1 nm). In all AS clones, the 
mean fibril diameters and their range were significantly larger than those of controls 
(P<0.05). Among AS clones, AS1 that exhibited the lowest level of LOX showed the 
largest fibril diameter (mean 99.1+43.2 nm; range 31.3-226.7 nm) followed by AS2 
clones (mean 66.9+21.6 nm; range 22.2-170.8 nm) and AS3 clones that exhibited LOX 
only slightly lower than controls (mean 58.4+19.6 nm; range 16.7-129.2 nm) (Figure 
2.6).Therefore, the fibril diameter and distribution range were inversely correlated with 
the level of LOX expression in the clones. The number of collagen fibrils were counted 
per square micron randomly from 6 areas and presented in Table 2.2. The number of 
fibrils in all S clones were significantly lower than those of the controls (P<0.05). 
In vitro mineralization assay– The result of in vitro mineralization assay is shown 
in Fig 2.7. The mineralization pattern of two controls, MC cells and EV clone, was 
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essentially identical to each other. In both cases, the formation of mineralized nodules 
was present at 2 weeks of culture and the number and size of mineralized nodule 
increased thereafter. In S clones, mineralized nodules were not observed in any clones 
even at week 4. In AS clones, a small number of mineralized nodules were observed at 
2 weeks of cultures and increased there after; however, the amounts of nodules in all AS 
clones were less than those of controls (Fig 2.7A). The quantitative analysis of Alizarin 
Red S stain extracted from the mineralized matrix confirmed the defective matrix 
mineralization observed in S and AS clones. The level of Alizarin Red extracted dye from 
the MC and EV were comparable but higher than those from S and AS clones (Figure 
2.7B) (P<0.05).  
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Table 2.1   The amount (moles/mole collagen) of total aldehydes and reducible and, non-
reducible cross-links in each clone are expressed as mean+S.D. ( - : decrease, * P<0.05, 
ANOVA) 
 DHLNL HLNL PYR Total 
Aldehydes 
% change of 
PYR  
AS1 0.354+0.064* 0.123+0.007 0.012+0.005* 0.500 -64.61 
AS2 0.448+0.023 0.138+0.025 0.014+0.003* 0.614 -56.92 
AS3 0.463+0.013 0.079+0.015* 0.019+0.010 0.580 -41.54 
MC 0.475+0.010 0.168+0.030 0.029+0.007 0.701 0 
EV 0.476+0.032 0.172+0.024 0.036+0.015 0.719 0 
S1 0.487+0.052 0.130+0.001 0.084+0.008* 0.783 156.92 
S2 0.514+0.021 0.140+0.022 0.100+0.013* 0.853 206.15 
S3 0.609+0.126* 0.127+0.003 0.117+0.010* 0.970 260.0 
 
Table 2.2   The fibril density (number fibrils per square micrometer) from each clone is expressed 
as mean+S.D. (* P<0.05, ANOVA) 
Clones Mean + S.D. 
AS1 93.2+48.2 
AS2 122.2+26.9 
AS3 132.7+27.4 
MC 129.8+49.2 
EV 130.5+42.0 
S1 59.0+24.0* 
S2 70.0+25.6* 
S3 72.7+17.6* 
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Figure 2.1 The level of LOX protein expression per dish in stable clones and controls. Cultured 
medium pooled during the first week of culture were analyzed by IP-WB analysis using anti LOX 
antibody. The immunoreactive bands at ~35 kDa can be detected in all stable clones and 
controls. S clones, S1, S2 and S3, possessed higher levels of LOX (S3>S2>S1) compared to 
controls, MC cells or EV clone. AS clones, AS1, AS2 and AS3, synthesized lower levels of LOX 
(AS3>AS2>AS1) compared to that of controls.  
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Figure 2.2 Cell proliferation rate of S and AS clones. Cell proliferation of each clones and 
controls were assessed by MTS cell proliferation assay. Note that cell proliferation was 
comparable among all cell types. (P>0.05, ANOVA) 
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Figure 2.3 Amounts of collagen cross-links and their precursor expressed in moles/mole of 
collagen at 2 weeks of cultures. Total aldehydes and DHLNL in all AS clones were lower and in 
all S clones were higher than those of controls. Non reducible crosslink represented as Pyr in 
clones and controls was shown as bar graph. S1, S2 and S3 clones exhibited significantly higher 
level while AS 1 and 2 exhibited significantly lower level than that of controls (* P<0.05, ANOVA). 
Figure 2.4 Total collagen content from culture matrix and medium at day 3 and 7 of the cultures 
expressed as microgram of collagen per 10
4
 cells in each dish. All S clones showed significantly 
lower collagen production compared to those of controls at each timepoint of study (*,# P<0.05, 
ANOVA) while AS1 and 2 produced more collagen significantly at day 7 (# P<0.05, ANOVA). 
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Figure 2.5 Cross-section of the collagen fibrils in the ECM at 3 weeks of cultures observed under 
TEM and their diameter. All S clones produced smaller collagen fibrils while all AS clones 
produced larger collagen fibrils than those of the controls. The S3 clone, highest LOX level, 
produced the smallest collagen fibrils while the AS1 clone, lowest LOX level, produced the largest 
collagen fibrils. (bar = 100 nm). 
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Figure 2.6 Distribution of the collagen fibril diameter in the ECM at 3 weeks of cultures observed 
under TEM and their diameter distribution, based on total numbers of 500 fibrils.  The fibril 
diameter in all S clones were significantly smaller while those of all AS clones were significantly 
larger than those of the controls (* P<0.05, ANOVA). The S3 clone, highest LOX level, produced 
the smallest collagen fibrils while the AS1 clone, lowest LOX level, produced the largest collagen 
fibrils.  
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Figure 2.7 In vitro mineralization assay. A. Mineralized nodules formed by the controls (MC and 
EV) at 2 and 4 weeks of cell culture from the clones (S and AS) and the controls (MC and EV). In 
S clones, mineralized nodules were not observed in any clones at any time-point of study while in 
the AS clones, the formed nodules were formed at week 2 of cultures and increased thereafter.  
The nodules of AS clones were lesser than those of controls. B. The quantitative assay at week4 
of cultures confirmed the defective mineralization in S and AS clones. (*P<0.05, ANOVA) 
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DISCUSSION 
 In bone, a specific spatial relationship between the two predominant 
components, collagen fibrils and mineral, is critical for the mechanical function (286, 
287), and the collagen fibrils apparently regulate the manner of mineral deposition and 
growth (288, 289). A number of studies indicate that the covalent intermolecular cross-
linking formed at the edge of the hole zones of the fibril, the putative nucleation sites, 
plays a crucial role in collagen mineralization (283, 290-292). We have reported that the 
manipulation of cross-linking pattern in MC cells through lysyl hydroxylase 2b affects the 
collagen fibrillogenesis, and matrix mineralization (293). The study indicates the 
importance of the type of collagen cross-links is an important factor to regulate collagen 
fibrillogenesis and matrix mineralization. Up to now, however, the effect of the quantity of 
collagen cross-links on mineralization has never been directly investigated. As 
described, LOX family enzymes are the only known family enzyme to initiate the process 
of cross-linking by oxidative deaminating the ε-amino groups on peptidyl Lys and Hyl 
residues in the N- and C-terminal telopeptides of collagen. In this study, by establishing 
and characterizing MC cell derived clones expressing higher and lower levels of LOX, 
we examined if the level of collagen cross-links plays a role in collagen fibrillogenesis 
and subsequent matrix mineralization.  
 The collagen phenotype produced by S and AS clones was investigated by 
analyzing the quantity and quality using HPLC and TEM. The total collagen content in 
culture media and matrix in S clones was markedly decreased while that in AS clones 
was increased. The collagen fibril observed under TEM in S clones was significantly 
smaller and those in AS clones showed diversed diameter and larger than those of 
controls. The findings in AS clones were similar to those treated with ßAPN (73, 222) or 
a procollagen C-proteinase inhibitor (225). In ßAPN treated cultures, the total collagen 
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synthesis was increased and collagen fibril diameters were diversed and larger than 
those observed in control group (73, 222). In PCP inhibitor treated cultures, an increase 
of collagen fibril diameters was detected while LOX activity was decreased (225). In S 
clones, however, the total collagen content and its fibril diameter showed opposite to 
those found in AS clones, i.e. decreased collagen content and larger fibril diameter 
compared to controls. These results indicate the effect of LOX on collagen production, 
fibrillogenesis and mineralization. Altered collagen fibrillogenesis and mineralization 
might be the consequence of altered collagen cross-linking as its pattern is associated 
with those processes (293-295). However, the underlying mechanism of how LOX 
controls the collagen production is not clear. The altered level of collagen production at 
as early as day 3 can be hardly explained by an increase or a decrease of collagen 
cross-linking since even immature cross-links begin to accumulate only after 1-2 weeks 
in osteoblast cultures (222, 295, 296). The increased collagen expression/production by 
the treatment of ßAPN have also been reported in chondrocyte cultures (223, 297). 
These data clearly indicate that LOX inhibition affects “early” cellular functions 
associated with increased collagen expression/synthesis. The upregulation of collagen 
mRNA seen in lathyritic animals during the early phase of bone fracture healing (239) 
also supports this notion. Thus, the effect of LOX on collagen production might be 
related to its recently identified cellular functions (134). Future studies need to be 
investigated to clarify this speculation. 
 The in vitro mineralization was severely impaired in all S clones and, to a certain 
extent, in AS clones. This phenotype might be explained based on the template stability, 
morphology proposed by Landis et al 1993 (289). However, the result in this study 
showed the critical importance of LOX for the physiological matrix mineralization. 
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 In conclusion, this study showed potential roles of LOX in modulating collagen 
production, fibrillogenesis and matrix mineralization in osteoblastic cultures. Some of 
those effects may be associated with the cellular function of LOX.  
CHAPTER IV 
 
STUDY II 
Lysyl oxidase regulates transforming growth factor-ß1 function in bone via 
its amine oxidase activity. 
Phimon Atsawasuwan, Michitsuna Katafuchi, Yoshiyuki Mochida, Masaru Kaku,  
Mitsuo Yamauchi 
 
Specific aims 
1. To elucidate the binding between LOX and TGF-ß1 in vitro and in bone matrix. 
2. To evaluate the role of LOX on TGF-ß activity by determination of the level of 
Smad 3 phosphorylation and TGF-ß1 induced matrix molecule mRNA 
expression. 
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ABSTRACT 
Lysyl oxidase (LOX), an amine oxidase critical for the initiation of collagen and 
elastin cross-linking, has recently been shown to regulate cellular activities possibly by 
modulating growth factor activity. In this study, we investigated the interaction of LOX 
with transforming growth factor-ß1 (TGF-ß1), a potent growth factor abundant in bone, 
and evaluated the effect of this interaction. The specific binding between LOX and TGF-
ß1 was demonstrated both by immunoprecipitation and glutathione-S-transferase pull 
down assay. Both molecules were co-localized in the extracellular matrix in culture and 
the binding complex was identified in the mineral-associated fraction of bone matrix. 
Furthermore, LOX suppressed TGF-ß1 induced Smad3 phosphorylation and collagen 
(I/V) expression but the effects were nullified by ß-aminopropionitrile. The suppression of 
Smad3 phosphorylation was not affected in the presence of catalase. The data indicate 
that LOX may bind to mature TGF-ß1 and regulate its signaling via its amine oxidase 
activity in bone, thus, may play an important role in bone remodelling and mineralization. 
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INTRODUCTION 
Lysyl oxidase (LOX) is a copper-dependent amine oxidase that initiates the 
process of covalent intra- and intermolecular cross-linking in collagen and elastin (34). 
The critical role of LOX in tissue stability is well exemplified by “lathyrism”, the condition 
where deleterious effects in connective tissues are caused by lathyrogens such as ß-
aminopropionitrile (ßAPN) (298). In lathyritic animals, bone is one of the most severely 
affected tissues revealing kyphoscoliosis, bone deformities, weakening of tendons and 
ligament attachments, dislocation of joints, weakening of skin and cartilage, hernias and 
dissecting or saccular aneurysm of the aorta (233-235, 239). ßAPN is a potent and 
irreversible inhibitor of LOX, and prevents cross-linking of immature collagen and elastin 
into mature, stable insoluble fibers. Therefore, it has been thought that the phenotypes 
seen in lathyritic animals are due to the lack of cross-linking. Several reports showed 
that ßAPN treated osteoblasts exhibited an increase in collagen production and 
abnormal fibrillogenesis (73, 222). Moreover, the similar collagen phenotypes were 
observed in ßAPN treated chondrocytes (223, 297). These examples of abnormal 
collagen production can be hardly explained by a decrease of collagen cross-linking 
since even immature cross-links begin to accumulate only after 1-2 weeks in osteoblast 
cultures (222, 295, 296). The upregulation of collagen mRNA was observed in lathyritic 
animals during the early phase of bone fracture healing as well (239).  
Recent reports, however, have revealed novel functions for LOX including the 
regulation of gene transcription and cellular functions. Though the mechanisms are still 
not clear, those functions could be associated with its ability to oxidize substrates other 
than collagen and elastin, such as Histone H1 and H2 (132), basic fibroblast growth 
factor (bFGF) (134), and hypoxia induced factor (299). Thus, lathyritic phenotypes may 
also be due in part to the loss of LOX control of cellular functions.  
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Our previous study (chapter III) has demonstrated that LOX expression is 
inversely correlated with collagen production in an osteoblastic cell culture system. This 
could be due to the LOX interaction/regulation of growth factors that regulate collagen 
expression, as some studies suggested (104, 134). Thus, we next investigated the 
potential LOX regulation of growth factors that are known to regulate collagen 
expression in bone. In bone, there are several major growth factors such as transforming 
growth factor-ß (TGF-ß), bone morphogenic proteins (BMPs), insulin-like growth factors 
(IGFs) and platelet derived growth factor (PDGF), tumor necrosis factor-α (TNF-α) and 
basic fibroblast growth factor (bFGF). Several studies has reported that insulin-like 
growth factors (IGF1 and 2) and TNF-α play some roles in collagen production (300-
307). Concerning the effects on collagen synthesis, bFGF and PDGF showed 
inconsistent results (303, 304, 308-311). However, considering the fact that LOX has a 
strong preference for basic proteins as its substrate (126), IGF1/2 (pI ~6.46 and 7.76) 
and TNF- α (pI ~7.02) may not be substrates for LOX. Type I collagen has been reported 
as a target gene of TGF-ß1 and BMPs in bone (252, 312-314) and that both are basic 
proteins (pI~8.59 and 8.5). During our initial study on the interaction between LOX and 
TGF-ß1/BMPs, we have found that LOX specifically binds to mature TGF-ß1 and 
suppresses its signaling.  TGF-ß1 is one of the most potent growth factors enriched in 
bone matrix modulating many aspects of bone physiology (see a review in (252)). TGF-
ß1 is secreted and stored as a small or large latent complex in bone matrix that can be 
released and activated by the action of osteoclasts (262, 263) and through other 
mechanisms. Numerous studies, though not always consistent, have shown that TGF-ß1 
stimulates recruitment and proliferation of osteoblast progenitors (254, 315) and 
stimulates matrix production including collagen, but rather inhibits late stage of 
osteoblast differentiation and matrix mineralization (256, 257) and osteocalcin 
expression (250, 316). It is also involved in the modulation of osteoclast differentiation 
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(258). The abundance of this growth factor with such potent effects on cells in a dynamic 
environment of bone clearly predicts the need for tight regulation of its biological 
activities.  
In this study, we have demonstrated that LOX binds to mature TGF-ß1 and 
inhibits its signaling through an amine oxidase activity. Furthermore, LOX and TGF-ß1 
form a complex in the mineralized matrix fraction in bone. Thus, LOX may play a pivotal 
role not only in collagen stability but also in regulation of TGF-ß activity which is critical 
for bone physiology and pathology.  
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EXPERIMENTAL PROCEDURES 
Antibodies and Proteins Used- These following antibodies were used in this 
study: Anti-V5 antibody (Invitrogen), anti-hemagglutinin (HA) antibody (Roche 
Diagnostics), anti-phosphoSmad3 antibody (Biosource), anti-glutathione S-transferase 
(GST) antibody (Sigma-aldrich), anti-Smad3, anti-phosphoSmad1,5,8,  anti-ß-actin 
antibodies (Cell signaling technologies), and anti-TGF-ß1 antibody (R&D systems). Two 
types of polyclonal anti-LOX antibodies were used, one purchased from Imgenex (anti-
LOXi) and another described in previous studies (anti-LOXh) (83, 317). Recombinant 
human TGF-ß1 protein (rhTGF-ß1) and recombinant human BMP-2 (rhBMP-2) were 
purchased from R&D systems.  
 Cell Lines and Culture Conditions- The human embryonic kidney (HEK) 293 cells 
were purchased from Clontech and maintained in Dulbecco’ s modified Eagle medium 
(Gibco) supplemented with 10% fetal bovine serum (Atlanta Biologicals), 100 U/ml 
penicillin (Gibco), and 100 g/ml streptomycin (Gibco) in a 5% CO2 atmosphere at 37 C. 
The medium was changed twice a week. The mouse calvaria-derived MC3T3-E1 (MC) 
cells were purchased from American Type Culture Collection (CRL-2593) and 
maintained in -minimum essential medium (Gibco) with the same supplements as 
above. The medium was changed twice a week. 
 Molecular cloning of mouse LOX cDNA- Total RNA was isolated from MC cells 
using TRIzol (Invitrogen). Two g of total RNA was used for reverse transcription and 
the cDNA was synthesized using the Omniscript RT kit (Qiagen). The cDNA containing 
the coding region of the mouse LOX (Genbank accession NM_010728) was generated 
by PCR using Hotstar Taq polymerase (Qiagen). The sequences of the primers were 
designed as shown in Table 3.1. The PCR product was then ligated into the 
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pcDNA3.1/V5-His-TOPO mammalian expression vector (Invitrogen), sequenced at the 
UNC-CH DNA sequencing facility (University of North Carolina, Chapel Hill, NC), and the 
plasmid containing LOX cDNA in a sense orientation (pcDNA3.1/V5-His/LOX) was 
obtained. To generate pcDNA3/V5-His/LOXdm (LOX with Lys314 and Tyr349 mutated 
resulting in an inactive LOX) (105), the coding sequences of LOX was subcloned from 
pcDNA3.1/V5-His/LOX by PCR and another additional two sets of primers for the 
mutation of Lys314 and Tyr 349 were designed using primers in Table 3.1. To generate 
pcDNA3/HA/LOX and pcDNA3/HA/LOXdm, the coding sequences of LOX was 
subcloned from pcDNA3.1/V5-His/LOX and pcDNA3/V5-His/LOXdm by PCR and the 
primers designed were shown in Table 3.1. The PCR products were digested with BamH 
I and Xho I and ligated into pcDNA3/HA mammalian expression vector (318), sequenced 
at the UNC-CH DNA sequencing facility. Two additional deletion mutant constructs of 
LOX, i.e. mature LOX (signal peptide-residue 1-16 and 162-411, LOX-HA) and LOX 
propeptide (signal peptide and propeptide: residue 1-161, LOPP-HA) were generated 
using 2 additional sets of primers as shown in Table 3.1, subcloned from 
pcDNA3/HA/LOX and sequenced at the UNC-CH DNA sequencing facility. 
Transfection, Immunoprecipitation and Western Blotting- 293 cells 
cotransfected with pcDNA3/HA/LOX vector and pcDNA3.1/V5-His vector harboring 
BMP-2, -4, -6, -7 (318) or pcDNA3.1-V5-His/TGF-ß1 using a FuGENE6 transfection 
reagent (Roche Diagnostics) according to the manufacturer’s instructions. pcDNA3.1-
V5-His/TGF-ß1 was generated as described. Briefly, PCR products were amplified using 
the normal mouse kidney cDNA  (BD Bioscience) as a cDNA template, purified and 
ligated into the pcDNA3.1/V5-His-TOPO mammalian expression vector, sequenced at 
the UNC-CH DNA sequencing facility, and the plasmid containing TGF-ß1 cDNA in a 
sense orientation (pcDNA3.1/V5-His/TGF-ß1) was obtained. The sequences of the 
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primers were designed and shown in Table 3.1. After transfection, the cultured media 
were collected, immunoprecipitated with either anti-V5 or anti-HA antibody. The samples 
were then incubated with protein A-sepharose 4B conjugate beads (Zymed 
Laboratories) for 30 min and the beads were washed twice with lysis buffer containing 
150mM NaCl, 20 mM Tris-HCl pH 7.5, 10mM EDTA, 1% Triton X-100, 1% deoxycholate, 
1.5% aprotinin, and 1mM phenymethylsulfonyl fluoride three times. Protein bound to the 
beads were dissolved in SDS sample buffer (100mM Tris HCl, pH 8.8, 0.01% 
bromophenol blue, 36% glycerol, and 4% SDS) in the presence of 10mM dithiothreitol 
(DTT), applied to 4-12% gradient SDS-PAGE, transferred onto a polyvinylidene fluoride 
membrane (Immobilon-P, Millipore), and subjected to Western blot analysis with anti-V5 
or anti-HA antibody. The immunoreactivity was visualized by an alkaline phosphatase 
(ALP) conjugate substrate kit (Bio-Rad). To determine whether LOX binds to LAP or 
mature TGF-ß, 293 cells were transiently transfected with the pcDNA3/HA/LOX, and 
either pcDNA3.1/V5-His/TGF-ß 1 or pcDNA3.1/V5-His/LAP, using Fugene6 transfection 
reagent. pcDNA3.1/V5-His/LAP was subcloned from pcDNA3.1/V5-His/TGF-ß1 by PCR 
and the primers were shown in Table 3.1. The PCR product was then ligated into the 
pcDNA3.1/V5-His-TOPO mammalian expression vector, sequenced at the UNC-CH 
DNA sequencing facility, and the plasmid containing LAP cDNA in a sense orientation 
(pcDNA3.1/V5-His/LAP) was obtained. The total amounts of plasmid were kept constant 
(2.5 g) by supplementing pcDNA3.1/V5-HisA (empty vector). The media were collected 
and subjected to immunoprecipitation and Western blot analysis in the same manner as 
described above. 
Generation of 293-derived Stable Clones Overexpressing LOX and MC Stable 
Clones Over/Underexpressing LOX– HEK293 cells were transfected with either 
pcDNA3.1/V5-His/LOX or pcDNA3.1/V5-His/LOXdm constructs as described above. 
 66 
After transfection, cell were cultured in the presence of 400 g/ml of G418 (Gibco) for 3-
4 weeks to select stably transfected clones. Positive clones derived from single G418-
resistant cells were then isolated by cloning rings and further grown in the same 
conditions. As a control, 293 cells were also transfected with an empty pcDNA3.1/V5-His 
A vector (EV, Invitrogen) and the clones (EV clones) were generated in the same 
manner.  
MC cells were transfected with pcDNA3.1/V5-His/LOX constructs (S and AS 
orientation) (see Chapter III) and pcDNA 3.1/V5-His A vector (empty vector [EV]; 
Invitrogen) using Fugene 6 transfection reagent (Roche). After 48 h, cells were 
trypsinized and plated at a low density.  Single cell-derived clones (S and AS clones) 
were isolated and maintained in the presence of 400 g/ml G418 (Invitrogen) for up to 4 
weeks.  
Purification of LOX-V5/His Fusion Protein – The 293-derived clones that 
synthesized the highest level of LOX-V5/His protein were cultured in 15 cm plates for 6 
days and the culture media were collected. LOX-V5/His fusion protein (LOX-V5) was 
purified using a nickel-nitrotriacetic acid-agarose resin (Qiagen) at 4˚C, and the purified 
proteins were pooled, dialyzed against 0.2 M sodium borate pH 8.2 and kept in -20˚C 
until use. The protein concentrations were measured by DC protein assay kit (Bio-Rad). 
To assess the purity of LOX-V5, aliquots of the sample were dissolved in SDS sample 
buffer containing 10 mM DTT, separated by 4-12% SDS-PAGE and subjected to 
Coomassie Brilliant Blue (CBB) R-250 staining or Western Blot analysis. For the latter 
analysis, two anti-LOX antibodies (anti-LOXi and anti-LOXh, see above) and anti-V5 
antibody were used. The major CBB stained protein band on the gel was cut and 
subjected to matrix assisted laser desorption ionization mass spectrometric analysis 
(MALDI-MS) at UNC-CH Proteomics Facility. LOXdm-V5/his fusion protein (LOXdm-V5) 
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was also purified in the same manner and subjected to LOX activity assay to verify the 
activity nullification of the mutations. 
 LOX Activity Assay- The LOX enzyme activity was measured using the Amplex 
Ultra Red fluorescence assay (128). Five or ten g of LOX-V5 with or without 500 M 
ßAPN were suspended in 2 ml of 0.1 M sodium borate, pH 8.2, containing, 1.2 M urea, 1 
unit/ml horseradish peroxidase (HRP) (Biochemika), 10 M Amplex red (Molecular 
Probes, Inc.), 10 mM 1,5-diaminopentane dihydrochloride (Sigma). The mixture was 
incubated for 30 min at 37C and the fluorescence intensities were measured with 
excitation and emission wavelength at 563 and 587 nm, respectively, using F2000 
spectrofluorometer (Hitachi). 
Glutathione S transferase (GST) Pull-down Assay- The sequences of the 
primers were designed to amplify the mature form of TGF-ß1 (residue number 279-390) 
and shown in Table 3.1. The PCR products were amplified using the normal mouse 
kidney cDNA as a cDNA template, purified and ligated into a pGEX-4T-1 vector (GE 
Healthcare) and transformed into BL21 strain of Escherichia coli (Stratagene). An empty 
pGEX4T-1 vector was also transformed into the bacterial cells to produce GST protein 
alone. After DNA purification, plasmids were analyzed by restriction enzyme digestion, 
sequenced, and the plasmid harboring the mature form of GST-TGF-ß1 (pGEX4T-1-
TGF-ß1) was obtained. After the bacteria transformed with pGEX4T-1-TGF-ß1 or 
pGEX4T-1 were cultured at 37 ºC for several hours, 250μM of isopropyl-D-1-
thiogalactopyranoside (IPTG, Sigma-Aldrich) was added to induce the synthesis of GST 
and GST-TGF-ß1 proteins. After incubating for 24 hours at 20˚C, the cultures were 
centrifuged, lysed in a buffer containing PBS and 1% Triton X-100, and sonicated for 20 
sec three times with an interval of 3 min on ice. The lysates were collected by 
centrifugation, incubated with glutathione-sepharose beads (GE Healthcare) overnight at 
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4ºC and the beads were extensively washed with PBS. The recombinant GST-TGF-ß1 
and GST proteins were then released with the elution buffer (10mM glutathione, 50mM 
Tris-HCl pH 8.0) at 4 ºC.  The purity of the recombinant proteins was assessed by SDS-
PAGE. The protein concentrations were measured by DC protein assay kit. Then GST 
pull down was performed in the following manner. Five g of of GST or purified GST-
TGF-ß1 fusion protein 2.5 or 5 g were incubated with 10 g of LOX-V5 in 50 mM Tris-
HCl, pH 8.0, with the presence or absence of 500 μM ßAPN for 1 h at 4C. Glutathione-
sepharose beads (GE Healthcare) were then added and further incubated for 30 min at 
4C. The beads were then washed three times with TBST buffer (0.02% Tween 20 
(Fisher scientific), and the proteins bound were released by boiling for 5 min in SDS 
sample buffer containing 10mM DTT, and subjected to Western blot analysis with anti-
V5 antibody. The immunoreactivity was visualized by ALP conjugate substrate kit. 
Direct binding of LOX and TGF-ß1 by immunoprecipitation- Twenty ng of 
rhTGF-ß1 (R&D systems) were incubated with 10 g of LOX-V5 in 50 mM Tris-HCl, pH 
8.0, containing in the presence or absence of 500 μM ßAPN for 1 h at 4C. The protein 
G-sepharose 4B conjugate beads (Zymed) were then added to the solutions and further 
incubated for 30 min. The sepharose-bound complexes were collected by centrifugation, 
washed three times with TBST buffer, and the proteins bound were released and 
subjected to Western blot analysis with anti-V5 antibody as described above.  
Laser-scanning Confocal Microscopy – The potential co-localization of LOX and 
TGF-ß1 was investigated in a MC culture system by a laser-scanning confocal 
microscopy. MC cells were cultured for 3 weeks as described above, washed with PBS 
and fixed with 10% formaldehyde for 10 min. Cell/matrix layer was then cut into 1 X 1cm 
pieces, placed on a glass slide and dried. The slides were then immersed in PBS and 
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treated with 20 μg/ml of Proteinase K (Roche Applied Science) for 10 min. Samples 
were incubated with two primary antibodies, i.e. anti-TGF-ß1 and anti-LOXi antibodies, 
in PBS containing 1.5% goat serum for 30 min, washed with PBS and incubated with 
species-specific fluorescence-labeled secondary antibodies, mouse Alexa Fluor 594 and 
rabbit Alexa Fluor 488 (Invitrogen), for 30 min each. After washing with PBS, the 
specimens were mounted and the immunofluorescence was observed under a Zeizz 
LSM5 Pascal at UNC-CH microscopy services laboratory.  
Identification of LOX-TGF-β1 complex in bone matrix- Femurs from fetal bovine 
animals were purchased from Aries Scientific (Texas) and kept at -80C until use. Both 
femoral heads were removed and the mid-shafts were longitudinally cut. After the bone 
marrow was removed and washed with cold PBS; bones were cut into small pieces, 
defatted with methylene chloride and methanol solution (2:1) overnight at 4C, washed 
with cold DDW and lyophilized. The bone fragments were then pulverized in liquid 
nitrogen using a freezer mill (Spex Certiprep), washed with cold distilled water, 
lyophilized and subjected to sequential extraction described by Termine et al. (319) with 
some modifications (320). Briefly, ~1 g of bone powder was first extracted with 5 ml of 
6M guanidine-HCl (GH), pH 7.4, for 2 days at 4oC, the supernatant was separated by 
centrifugation at 15,000Xg for 30 min, exhaustively dialyzed against cold distilled water 
and lyophilized (G1 representing the matrix molecules that are not associated with 
mineral). The residue (mineral-associated) was then demineralized with 0.5M EDTA, pH 
7.4, for 2 weeks at 4oC with several changes of EDTA, the supernatant was separated 
by centrifugation as described above, dialyzed against cold distilled water and 
lyophilized (E representing soluble matrix molecules associated with mineral). The 
residue was further extracted with 5 ml of 6 M GH, pH 7.4, for 2 days at 4oC, the extract 
was collected by centrifugation, dialyzed and lyophilized as described above (G2 
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including mineral-associated, insoluble matrix). All fractions were weighed, dissolved in 
lysis buffer and centrifuged. The protein concentration in the supernatant was 
determined by a DC protein assay kit. Fifteen g of proteins in each fraction was 
dissolved in SDS sample buffer and subjected to WB analysis with either anti-LOXi or 
anti-TGF-ß1 antibodies. The immunoreactivity was visualized by ALP conjugated 
substrate kit. In order to confirm the specific binding, various amounts of E fraction (500, 
1000 and 2000 g of protein) was immunoprecipitated with either 5 l of anti-LOXi or 
anti-LOXh antibodies or 5 l of rabbit non-immune serum (negative control) in lysis 
buffer overnight at 4C. Then protein G-sepharose 4B conjugate beads were added, 
incubated for 15 min at 4oC and the beads were washed 3 times with lysis buffer. The 
immunocomplex was then released from the beads and subjected to Western blot 
analysis with anti-TGF-ß1 antibody. The immunoreactivity was visualized by ALP 
conjugate substrate kit. 
Effect of LOX on Smad phosphorylation- To determine the effect of LOX on the 
TGF-ß1 activity, MC cells were plated onto 35 mm culture dishes at a density of 2.0 
x105/dish in duplicate and cultured in -minimum essential medium (Gibco) with the 
same supplements as described in the culture condition section. MC cells were 
transiently transfected with 1, 2.5 and 5 g of the pcDNA3.1/V5-His/LOX using Fugene6 
transfection reagent. After 48 hours, cells were treated with rhTGF-ß1 (5 ng/ml) for 30 
min in the presence or absence of 300 M ßAPN or 200U/ml of catalase. Another set of 
the cells was transiently transfected with 5 ug of pcDNA3.1/V5-His/LOXdm and the cells 
were treated with rhTGF-ß1 in the same manner. The cells were lysed with 400 l RIPA 
buffer containing 150 mM NaCl, 50 mM Tris-HCl pH 8.0, 1% NP-40, 0.1% SDS, 0.5% 
deoxycholate, 1% aprotinin, and 1 mM phenymethylsulfonyl fluoride by continuous 
shaking for 1 hour at 4C then centrifuged. The supernatants collected were then 
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subjected to Western blot analysis with anti-phospho Smad3 (Biosource) and anti 
Smad3 antibodies (Cell Signaling). The intensity of phospho-Smad3 protein from each 
sample was normalized by the amount of total Smad3 protein using Scion Image 
software. LOX in the media was quantified by immunoprecipitation followed by Western 
blot analysis with anti-LOXi antibody. In a parallel set of experiment, cells were treated 
with 100 ng/ml of rhBMP-2 instead of rhTGF-ß1 and the cell lysates were subjected to 
Western blot analysis with anti-Smad1,5,8 and anti ß-actin (Cell signaling technologies). 
In another set of experiment, MC cells were cultured as described above. On the 
following day, 2.5 or 5 μg of LOX-V5 or a combination of 5 μg of LOX-V5 with or without 
300 μM of ßAPN or 300 μM ßAPN alone was added to the cells. Cells were then treated 
with 5 ng/mL of rhTGF-ß1 for 30 min, and the phosphorylation of Smad3 was evaluated 
in the same manner as described above.  
To determine the effect of the level of LOX on the TGF-ß1 activity, MC, EV, S 
and AS clones were plated onto 35 mm culture dishes at a density of 2.0 x105/dish in 
duplicate and cultured in -minimum essential medium with the same supplements as 
described in the culture condition section. After 48 hours, cells were treated with rhTGF-
ß1 (5 ng/ml) for 30 min. The cells were lysed then centrifuged and supernatants 
collected were then subjected to Western blot analysis with anti-phospho-Smad3 and 
anti Smad3 antibodies. The intensity of phospho-Smad3 protein from each sample was 
normalized by the amount of total Smad3 protein using Scion Image software. 
Quantitative Real-time PCR- MC cells were cultured in the same manner as 
described in the Smad3 phosphorylation western blotting experiment. On the following 
day, 2.5 or 5 μg of LOX-V5 or a combination of 5 μg of LOX and 300 μM of ßAPN was 
added to the cells. Cells were then treated with 5 ng/mL of rhTGF-ß1 and further 
cultured for 24 hours. Total mRNA was extracted by TRIzol reagent. Two g of total 
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RNA was used for reverse transcription and the cDNA was synthesized using the 
Omniscript RT kit. Real-time PCR was performed using sequence specific primers and 
ABI Prism 7000 Sequence detection system (Applied Biosystems). Primers used are as 
follows: COL1a2 (#Mm00483888_m1) and COL5a1 (#Mm00489342_m1) and GAPDH 
(#4308313). The analyses were performed in triplicate for three independent 
experiments to confirm reproducibility of the results. SB431542, ALK 4,5 and 7 inhibitors, 
were used as negative controls in the experiment (321). The mRNA expression relative 
to GAPDH was determined and the fold changes were calculated using the values of 
rhTGF-ß1 addition only as a calibrator by means of 2-ΔΔCT method (74). 
RNA interference- MC cells were plated onto 35 mm culture dishes at a density 
of 5.0x104/dish in duplicate and cultured in the same manner as described above. On 
the following day, cells were transfected with 3.75 g of LOX siRNA ID#156159, 156160, 
156161 or Silencer negative control AM4611 (Ambion) using siPORT Amine transfection 
agent (Ambion). Forty-eight hours after transfection, the cells were treated with 5 ng/ml 
of rhTGF-ß1 for 30 min Smad3 phosphorylation was examined in the same manner as 
described above. The suppression of LOX protein in the media was verified by 
immunoprecipitation followed by Western blot analysis with anti-LOX antibodies 
Statistical analyses– All statistical analyses were performed using Sigma stat 
software. Data are expressed as mean+SD. Statistical differences were determined by 
one-way ANOVA followed by a Tukey-Kramer multiple comparison test at P=0.05. 
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Table 3.1  Primers list of constructs used in the study. 
construct Forward primer 
Reverse primer 
fLLOX-V5/His 5’-CCCGGTCTTCCTTTTTCTCCTAGCC-3’ 
5’-ATACGGTGAAATTGTGCAGCCTGA-3’ 
fLLOXdm-V5/His 5’-GCTGAAGGCCACGCAGCAAGCTTCTGT-3’ 
5’-ACAGAAGCTTGCTGCGTGGCCTTCAGC-3’  and 
5’-TGTTATGACACCTTTGCGGCAGACATA-3’ 
5’-TATGTCTGCCGCAAAGGTGTCATAACA-3’ and  
5’-CCCGGTCTTCCTTTTTCTCCTAGCC-3’ 
5’-ATACGGTGAAATTGTGCAGCCTGA-3’ 
fLLOX-HA and 
fLLOXdm-HA 
5’-GCGGATCCATGCGTTTCGCCTGGGCTGTGCTC-3’ 
5’-GCCTCGAGATACGGTGAAATTGTGCAGCCTGAGGC-3’ 
LOX-HA 5’-CTTCTCCGCTGCGACGACCCCTACAATCCCTAC-3’ 
5’-GTAGGGATTGTAGGGGTCGTCGCAGCGGAGAAG-3’ and 
5’-GCGGATCCATGCGTTTCGCCTGGGCTGTGCTC-3’ 
5’-GCCTCGAGATACGGTGAAATTGTGCAGCCTGAGGC-3’ 
LOPP-HA 5’-GCGGATCCATGCGTTTCGCCTGGGCTGTGCTC-3’ 
5’-GCCTCGAGGCCCACCATGCGATCTATGTGGCT-3’ 
TGF-ß1-V5 5’-CATGCCGCCCTCGGGGCTG-3’  
5’-GCTGCACTTGCAGGAGCGC-3’. 
LAP-V5 5’- GCTGCACTTGCAGGAGCGC -3’ 
5’- TCTCCGGTGCCGTGAGCTGTG -3’ 
Mature GST-TGF-ß1 5' GCGAATTCGCCCTGGATACCAACTATTGCTTC 3' 
5' GCCTCGAGTCAGCTGCACTTGCAGGAGCGCAC 3' 
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RESULTS 
Mature LOX binds to mature TGF-ß1– The binding of LOX to TGF-ß1 and some 
of the osteogenic TGF-ß superfamily members, i.e. bone morphogenetic proteins (BMP-
2, -4, -6 and -7), was investigated by co-expressing those proteins with two types of tag 
(HA for LOX and V5 for other proteins) followed by immunoprecipitation (IP) and 
Western blot (WB) analysis (Fig 3.1A). When IP and WB were performed with either 
anti-V5 or -HA antibody alone, V5-tagged TGF-ß1 (Fig 3.1A, lane 6, lower panel), V5-
tagged BMPs (Fig 3.1A, lanes 2-5, lower panel), or HA-tagged LOX (Fig 3.1A, lanes 2-7, 
middle panel) was detected at the expected molecular weight of each protein 
demonstrating the presence of those proteins. Of the proteins tested, only TGF-ß1 was 
shown to bind LOX (Fig 3.1A, lane 6, upper panel). Any of the BMPs tested did not show 
appreciable binding (Fig 3.1A, lanes 2-5, upper panel). Even when higher levels of 
BMP2 (2-fold) were expressed; no binding was observed (data not shown). The binding 
of LOX to TGF-ß1 was further characterized. Fig 3.1B showed that the binding of LOX to 
full-length TGF-ß1 occurred in a dose dependent manner (Fig 3.1B, lanes 3-5, upper 
panel) while LAP (propeptide of TGF-ß1) alone did not bind to LOX at various doses (Fig 
3.1B, lanes 7-9, upper, indicating that LOX bound specifically to mature TGF-ß1. Then, 
we generated HA-tagged full length LOX (residue 1-411, fLOX-HA) (Fig 3.2A, 1) and two 
deletion mutant constructs of LOX, i.e. mature LOX (signal peptide-residue 1-16 and 
162-411, LOX-HA) (Fig 3.2A, 2) and LOX propeptide (signal peptide and propeptide: 
residue 1-161, LOPP-HA) (Fig 3.2A, 3). One of these proteins and TGF-ß1-V5 were then 
transiently co-expressed by 293 cells and the binding was assessed by IP and WB 
analysis in the same manner as described above. Three different levels of TGF-ß1 were 
expressed for the binding assay (Fig 3.2B, lower panel). The immunoreactive bands 
were detected in a dose dependent manner for fLOX-HA (Fig 3.2B, upper panel) and 
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LOX-HA (Fig 3.2B, upper middle panel) but not LOXPP-HA (Fig 3.2B, lower middle 
panel). When fLOX-HA was expressed, both full length (55 kDa) and mature forms (35 
kDa) of LOX were synthesized (shown by an arrow in the upper panel of Fig 3.2B). 
Though fLOX-HA was partially overlapped with the IgG heavy chain, the dose-
dependent binding was readily observed for both fLOX and mature LOX. These results 
indicate that the binding of LOX to TGF-ß1 occurs via the mature form of LOX but not its 
propeptide domain.  
Direct binding of LOX to TGF-ß and the effect of ßAPN – To determine if LOX 
binds to TGF-ß1 directly, we performed GST pull down assay by using GST fused 
mature TGF-ß1 (GST-TGF-ß1) and purified LOX-V5 protein. First the purity of LOX-V5 
(both full length and mature) was verified by SDS-PAGE and WB analyses. When 
stained with CBB, 4 bands were observed at 28 and 35 kDa corresponding to the 
molecular sizes of mature LOX and 48 and 55 kDa corresponding to those of full-length 
LOX with V5 tag, respectively. The LOX-V5 was further analyzed by WB analysis using 
two anti-LOX antibodies (anti-LOXi and anti-LOXh) and anti-V5 antibody (Fig 3.3A, lanes 
3, 4 and 5, respectively). The 28 kDa band was indeed immunoreactive to 3 antibodies 
but not normal rabbit serum (Fig 3.3A, lane 2). The 28 and 35 kDa band were cut and 
subjected to protein identification using MALDI-MS at UNC-CH Proteomics Facility and 
four tryptic peptides separated were all identified in both bands as portions of LOX (res 
225-231, 246-254, 263-277, 372-391 respectively) (accession protein# NP_034858.1), 
thus unequivocally confirming its identity. LOX-V5 was then subjected to amine oxidase 
assay reported by Palamakumbura AH and Trackman PC (128). The activity increased 
in a dose-dependent manner and nullified by the addition of ßAPN demonstrating that 
the LOX-V5 still retained activity after purification (Fig 3.3B). LOXdm-V5 was also 
subjected to amine oxidase assay and showed no activity at all (data not shown).  After 
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we obtained active LOX-V5, we performed GST pull down using active LOX-V5 and 
GST-TGF-ß1. The positive immunoreactive bands of LOX-V5 were detected when LOX-
V5 was incubated with GST-TGF-ß1 in a dose-dependent manner (Fig 3.4A, lanes 3 and 
4) but not with GST alone (Fig. 3.4A, lanes 2 and 5). LOX-V5 was also verified in Fig. 
4A, lane 1. The binding of LOX-V5 to GST-TGF-ß1 was not affected by the presence of 
500 μM ßAPN (Fig. 3.4A, lanes 6 and 7). The direct binding was also confirmed by IP-
WB analysis using LOX-V5 and rhTGF-ß1. When those two proteins were mixed and 
immunoprecipitated with anti-V5 antibody and subjected to WB analysis with anti-TGF-
ß1 antibody, the TGF-ß1 was detected and it was not interfered in the presence of ßAPN 
as well (Fig. 3.4B). 
Co-localization of LOX and TGF-ß1 in an osteoblast culture system –To 
investigate the endogenous association of LOX with TGF-ß1 in vitro, we used 
preosteoblastic cell line, MC cells, and the localization of both proteins was assessed by 
the laser scanning fluorescence microscopy. In Fig. 3.5, TGF-ß1 was shown in red (Fig. 
3.5A), LOX in green (Fig. 3.5B) and co-localizalization of the two in yellow in the merged 
image (Fig. 3.5D). A fibrous extracellular matrix (ECM) structure between cell bodies 
was identified in the culture and confirmed by differential interference contrast (DIC) 
image (Fig 3.5C). The result demonstrated that both molecules were co-localized in the 
ECM of the culture (Fig. 3.5D) suggesting the close association of both proteins in the 
preosteoblastic cell matrices (Fig. 3.5E). 
Identification of a LOX-TGF-ß1 complex in bone matrix – To investigate whether 
or not a LOX-TGF-ß1 complex is indeed present in bone, bone matrix was fractionated 
into G1, E and G2 by sequential extraction. The equal amount of protein from each 
fraction was subjected to WB analysis with anti-LOXi and anti-TGF-ß1 antibodies. Both 
LOX and TGF-ß1 in bone matrix were identified in mineral-associated matrix fractions (E 
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and G2) but not in G1 fraction though their relative distribution in each fraction was 
different (Fig. 3.6A). This suggested that LOX and TGF-ß1 were both closely associated 
with mineral in bone matrix. Then various amounts of E fraction (500, 1000 and 2000 
μg), which is more soluble and abundant than G2, were then subjected to IP with anti 
LOXi and WB with to investigate their potential endogenous binding in bone matrix. The 
results shown in Fig. 3.6B demonstrated that the endogenous binding between LOX and 
TGF-ß1 occurs in a dose dependent in bone matrix.  
Effect of LOX enzymatic activity on TGF- ß1 signaling– Since the binding of LOX 
to TGF-ß1 in both in vitro and in vivo was confirmed, the effect of LOX on TGF-ß1 
signaling and its potential mechanism were then examined. MC cells were transiently 
transfected with various amounts of pcDNA3.1/LOX/V5-His in the presence or absence 
of 300 M BAPN or 200U/ml of catalase. The LOX protein level in each treatment group 
was evaluated by IP-WB analysis with anti-LOX antibody (Fig 7A,B, lower panel). Then 
rhTGF-ß1 was added to those groups and the phosphorylation of Smad3 
(phosphoSmad3 protein relative to the total Smad3 protein) was evaluated. Without the 
addition of rhTGF-ß1, cells overexpressing EV, LOX did not induce Smad3 
phosphorylation (Fig 3.7A, lanes 1 and 2, Fig 3.7B, lanes 1-3). The addition of TGF-ß1 in 
the EV group induced Smad3 phosphorylation (Fig 3.7A, lane 3). However, the 
phosphorylation level was diminished with the presence of LOX in a dose-dependent 
manner (Fig 3.7A, lanes 4-6). The LOX-mediated inhibition was not affected in the 
presence of catalase (Fig 3.7A, lane 7) but completely rescued in the presence of ßAPN 
(Fig 3.7A, lane 8). When MC cells were transfected with pcDNA3.1/LOX/V5 and 
pcDNA3.1/LOXdm/V5-His in the same amount, in the similar settings, the inhibition of 
Smad3 phosphorylation was observed in cells overexpressing LOX (Fig 3.7B, lane 5) but 
not in LOXdm (inactive LOX) (Fig 3.7B, lane 6) compared to EV group (Fig 3.7B, lane 4)  
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In stable cell clones, without the addition of rhTGF-ß1, Smad3 phosphorylation 
could not be detected (Fig 3.8, lane 2). The addition of TGF-ß1 significantly induced 
Smad3 phosphorylation in all groups of cells (Fig 3.8, lanes 1, 3-9). Moreover, the 
phosphorylation level in all S clones were diminished and in all AS clone were enhanced 
corresponded to the level of LOX expression in each clone (Fig 3.8, lanes 4-9) while that 
in all AS clones were enhanced respectively (Fig 3.8, lanes 7-9) compared to controls 
(MC and EV) (Fig 3.8, lanes 1 and 3). 
In another set of experiments, using MC cells, the effect of exogenous LOX-V5 
addition with or without ßAPN on TGF-ß1 signaling was further evaluated. The results 
are shown in Fig 3.9. Without TGF-ß1 treatment, the presence or absence of LOX or 
ßAPN did not induce Smad3 phosphorylation (Fig 3.9, lanes 1-3). The phosphorylation 
was induced with TGF-ß1 (Fig 3.9, lane 4), but it was significantly diminished with the 
addition of LOX-V5 in a dose-dependent manner (Fig 3.9, lanes 6 and 7). However, this 
LOX mediated inhibition was rescued in the presence of ßAPN (Fig 3.9, lane 7). 
Moreover, when ßAPN without exogenous LOX-V5 was added combined with TGF-ß1, 
Smad3 phosphorylation was slightly more enhanced in comparison to that of TGF-ß1 
alone (Fig 3.9, lane 8 vs. 3). Since ßAPN alone did not induce Smad3 phosphorylation 
(Fig 3.9, lane 3), this result suggests the presence of endogenous LOX in the cultured 
medium that was inhibited by ßAPN. 
To confirm that the inhibitory effect of LOX is specific to TGF-ß1 not BMPs, the 
effect of LOX on BMP-2 induced signaling was then examined. MC cells were transiently 
transfected with various amounts of pcDNA3.1/V5-His/LOX in the presence or absence 
of 300M ßAPN. The LOX protein level in each treatment group was evaluated by IP-
WB analysis with anti-V5 antibody (Fig 3.10, lower panel). Then rhBMP-2 was added to 
those groups of cells overexpressing active LOX and the phosphorylation of Smad1,5,8 
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was evaluated. Regardless the addition of BMP-2, cells overexpressing EV or LOX did 
not induce Smad1,5.8 phosphorylation either in the presence or absence of ßAPN (Fig 
3.10, upper panel, lanes 3-8). The signal of Smad1,5,8 phosphorylation was normalized 
with the level of ß-actin (Fig 3.10, middle panel).  
Effect of LOX on TGF-ß induced ECM molecules mRNA expression – Type I and 
type V collagen mRNA expression were quantified after the addition of exogenous LOX 
either with or without ßAPN (Fig 3.11).  The expression levels of both types of collagen 
were upregulated upon TGF-ß1 treatment (5ng/ml)(Fig3.11,lane 4), however, in the 
presence of LOX (2.5 and 5 ug), the level was decreased respectively (Fig 3.11, lane 5, 
6). Moreover, an addition of 300μM ßAPN rescued LOX-mediated TGF-ß1 inhibition (Fig 
3.11, lane 7). Note that the expression of Col5A1 was more responsive to TGF-ß1 
addition than that of Col1A2. 
Effect of LOX RNA interference on TGF-ß signaling – In addition to verify the 
effect in AS, another loss-of-function experiment was performed by RNAi technology. 
MC cells were transiently transfected with Silencer negative control or three different 
constructs of LOX siRNA. LOX protein levels in the media were lower (20-80%) in the 
cell groups that were transfected with siRNA than that of negative control (Fig 3.12, lane 
2-5, upper panel). The LOX level was the lowest when cells were transfected with 3 
siRNA constructs combined (Fig 3.12, lane 2).  In comparison to the negative control 
(Fig 3.12, lane 1), the TGF-ß1 induced Smad 3 phosphorylation was significantly 
increased in all siRNA transfected groups (Fig 3.12, lane 3, 4 and 5) and the increase 
level was the highest in the combined group that exhibited the lowest LOX protein level 
(Fig 3.12, lane 2). Without rhTGF-ß1, LOX siRNA transfection alone did not induce 
Smad3 phosphorylation (Fig 3.12, lane 6-10). This result implicated that the knock down 
of endogenous LOX in the culture leads to the higher levels of TGF-ß1 signaling.
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Figure 3.1 Binding of LOX to TGF-ß1/BMPs. A, Binding of LOX to TGF-ß1 (upper panel, lane 6), 
but not to any BMPs (upper panel, lanes 2-5) was clearly observed. The expression levels of LOX 
and BMPs/TGF-ß1 were verified by IP-WB analyses with anti-HA antibody (middle panel) and 
with anti-V5 antibody (lower panel), respectively. An asterisk indicates Ig light chain. B, Binding of 
LOX to TGF-ß1 in a dose-dependent manner (upper panel, lanes 3-5 indicated by an arrowhead) 
but not to LAP with any doses tested (upper panel, lane 7-9). The expression levels of LOX and 
TGF-ß1/LAP are shown in the middle and lower panels, respectively. Note that LOX binds to 
TGF- ß1; LAP: latency associated peptide. Molecular weights are shown on the right. 
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Figure 3.2 LOX constructs and their binding to TGF-ß1 by IP-WB. Left panel: a diagram of LOX 
constructs. Right panel: the binding between each LOX-HA construct product and TGF-ß1-V5/His 
by IP with anti-V5 antibody followed by WB with anti-HA antibody. Various expression levels of 
full-length TGF-ß1 for the assay are shown by WB with anti-V5 antibody at the bottom. Note that 
all of the LOX construct products [LOX-HA (1), LOXΔpro-HA (2), LOXdm-HA (4)] except LOPP 
(3) show binding to TGF-ß1-V5/His in a dose-dependent manner except LOXpropeptide. Note 
that LOXdm was shown the similar pattern as LOX-HA and an arrow indicates the full-length LOX 
but the WB showed only mature form area. Asterisks represent heavy and light chains of IgG. AF 
represents alanine (A) and phenylyalanin (F) which replaced tyrosine and lysine in LTQ domain. 
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Figure 3.3 Purity and activity of LOX-V5/His protein. (a) LOX-V5/His protein was stained with 
CBB (lane 1), immunostained with normal rabbit serum (RS; lane 2), anti-V5 antibody (lane 3), 
anti-LOX antibody (Imgenex) (lane 4) and that provided by Dr. Csiszar, U Hawaii (lane 5). An 
immunopositive band at ~35kDa (~30kDa LOX + ~5kDa V-5/His tag) was detected with all the 
antibodies used except RS. (b) Amine oxidase activity of LOX-V5/His protein. Note that an amine 
oxidase activity of LOX-V5/His protein is retained and increased in a dose-dependent manner, 
and the activity was completely blocked with 500μM of ßAPN. 
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Figure 3.4 Direct binding of LOX to TGF-ß1. A, LOX-V5/His protein was incubated with GST-
TGF-ß1 or GST alone, and subjected to GST pull down assay. The binding of GST-TGF-ß1 (lane 
3,4), not GST alone (lane 2), to LOX-V5/His was clearly detected and, moreover, the binding was 
not affected by the presence of ßAPN. Note that the binding is detected in a dose-dependent 
manner (lanes 6 and 7). Note that LOX-V5 in lane 1 was not pulled down with GST agarose. The 
amounts of the GST proteins and peptide added (input) are shown in the lower panel. 10μg of 
LOX-V5 protein added, BAPN: -aminopropionitrile. B, LOX-V5/His protein was incubated with 
rhTGF-ß1 either in the presence of absence of ßAPN. ßAPN did not affect the binding between 
LOX and TGF-ß1 (upper panel). The amounts of the rhTGF-ß1 (input) are shown in lower panel. 
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Figure 3.5 Co-localization of LOX and TGF-ß1 in a MC cell culture system. After 3 weeks of 
culture, immunofluorescence staining for LOX and TGF-ß1 was carried out and observed under 
LSCM (see text for details). (a) TGF-ß1 shown in red, (b) LOX in green, (c) Merged image 
showing co-localization of the two in yellow, (d) Differential interference contrast (DIC) image 
confirming fibrous ECM (arrowhead). 
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Figure 3.6 Binding of LOX and TGF-ß1 in bone extracellular matrix. A, Presence of LOX and 
TGF-ß1 proteins in bone matrix extracts. WB analyses were performed with anti-LOX antibody 
(upper panel), anti-TGF-ß1 antibody (middle panel), and normal rabbit serum (RS) (upper panel). 
The immunoreactive bands for LOX and TGF-ß1 were identified at the expected molecular weight 
in E and G2 fraction of bone (lanes 2 and 3), but not in G1 fraction of bone (lane 1). No 
immunoreactive bands were detected using RS (upper panel). G: guanidine-HCl, E: EDTA, G1: 
non-mineral associated fraction, E: mineral-associated, soluble fraction, G2: mineral-associated, 
insoluble fraction. LOX protein or recombinant human TGF-ß1 protein was subjected to WB 
analyses for positive controls (lane 4). B, Presence of LOX-TGF-ß1 binding complex in bone E 
extract. Note that immunopositive bands of TGF-ß1 are clearly detected in a dose-dependent 
manner (Middle panel, lanes 2-4) when IP-WB analyses were performed (IP; anti-LOX antibody, 
WB; anti-TGF-ß1 antibody), but absent from a negative control (normal rabbit serum, lane 1). The 
immunopositive band was also observed when another anti-LOX antibody was used (lane 5). The 
amount of LOX is shown in lower panel. +, ++, +++: 500, 1000 and 2000 g of protein.  
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Figure 3.7  Effect of LOX overexpression on TGF-ß signaling in osteoblasts (MC). A. The levels 
of Smad3 phosphorylation upon 30-minute incubation with TGF-ß1 (5ng/ml) (upper panel, lanes 
4-6) were decreased in a dose dependent manner of LOX compared to those of controls (upper 
panel, lanes 3). The inhibited Smad3 phosphorylation was enhanced upon TGF-ß1 treatment in 
the presence of 300M ßAPN (upper panel, lane 8). The presence of catalase 200U/ml did not 
affect the inhibition effect of LOX on TGF-ß signaling (upper panel, lane 7). The levels of Smad 3 
phosphorylation were normalized to those of Smad3.The level of LOX expression was 
determined by IP-WB with anti LOX antibody (lower panel);* P<0.05 compared to control (lane 3). 
B. In the cell transfected with LOXdm (upper panel, lane 6), the signal of smad3 phosphorylation 
was almost comparable to control (upper panel, lane 4) but still inhibited by the presence of LOX 
(lane 5), * P<0.05 compared to control (lane 4) 
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Figure 3.8   Effect of over/underexpression of LOX on TGF-ß signaling in MC cells. Note that the 
expression levels of Smad3 phosphorylation upon 30-minute incubation with TGF-ß1 (5ng/ml) 
after normalized with Smad3 (middle panel) were lower in all S clones (upper panel, lanes 4-6) 
while those in AS clone were higher (upper panel, lane 7-9) compared to those of control cells, 
MC and EV (lanes 1 and 3). The LOX level was shown in lower panel. 
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Figure 3.9  Effect of exogenous LOX protein on TGF-ß signaling in osteoblasts (MC). The levels 
of Smad3 phosphorylation upon 30-minute incubation with TGF-ß1 (5ng/ml) (upper panel, lanes 
5-6) were decreased in a dose dependent manner of LOX compared to those of controls (upper 
panel, lanes 4).  The inhibited Smad3 phosphorylation was enhanced upon 30 minutes of TGF-ß1 
treatment in the presence of 300M ßAPN (upper panel, lane7). In the presence of ßAPN only, 
the signal was increased compared to those of controls (upper panel, lane 8). Without TGF-ß 
induction, the levels of Smad 3 phosphorylation were not detected (upper panel, lane 1-3). The 
levels of Smad3 phosphorylation were normalized to those of Smad3 (lower panel).  
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Figure 3.10  Effect of LOX overexpression on BMP signaling in osteoblasts (MC). The levels of 
Smad 1,5,8 phosphorylation upon 30-minute incubation with BMP-2 (100ng/ml) (upper panel, 
lanes 3-8) were investigated. The Smad3 phosphorylation was not changed upon the treatment in 
any dose of LOX plasmid transfection (upper panel, lane 4-6) compared to those of controls 
(upper panel, lane 3). The Smad 1,5,8 phosphorylation was not changed upon BMP-2 treatment 
in the presence of 300M ßAPN (upper panel, lane7). The levels of Smad 1,5,8 phosphorylation 
were normalized to those of ß-actin (middle panel).The level of LOX expression was determined 
by IP-WB with anti V5 antibody (lower panel).  
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Figure 3.11  Effect of LOX on TGF-ß induced type I and type V collagen expression in 
osteoblasts by real-time PCR. Note that the expression levels of both types of collagen were 
upregulated upon 24-hour incubation with TGF-ß1 (5ng/ml)(lane 4), however, in the presence of 
LOX (2.5 and 5 ug), the level was decreased respectively (lane 5, 6). Moreover, an addition of 
300μM ßAPN rescued LOX-mediated TGF-ß1 inhibition (lane 7). LOX: LOX-V5/His 
protein.*P<0.05. 
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Figure 3.12  Effects of LOX suppression on TGF-ß signaling by RNA interference. The levels of 
Smad3 phosphorylation upon TGF-ß1 treatment (5ng/ml) were higher when LOX siRNA was 
performed (middle panel, lane 2-4) compared to control siRNA treatment (middle panel, lane 1). 
Without TGF-ß1 induction, the levels of Smad 3 phosphorylation were not detected (middle panel, 
lane 6-10). The levels of Smad3 phosphorylation were normalized to those of Smad3 (lower 
panel). The level of LOX expression was determined by IP-WB with anti LOX antibody (upper 
panel).  
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DISCUSSION 
Bone matrix is primarily composed of type I collagen and mineral such as 
hydroxyapatite. Bone matrix has been reported to store high concentrations of several 
growth factors that can affect the behaviour of connective tissue cells including 
transforming growth factor-ß (TGF-ß) and a set of bone morphogenic proteins (BMPs). 
TGF-ß1 is the prototypic member of the superfamily, and bone ECM is a major storage 
site in the body for this growth factor (247). In bone, TGF-ß1 plays pivotal roles in many, 
if not all, aspects of the tissue development, remodeling, mechanical properties and 
aging (250-252). Numerous studies, though not always consistent, have shown that 
TGF-ß1 stimulates recruitment and proliferation of osteoblast progenitors (253, 254), 
stimulates matrix production such as collagen, fibronectin, osteopontin, osteonectin, 
proteoglycans, but inhibits osteocalcin (250, 322), inhibits late stage of osteoblast 
differentiation and matrix mineralization (257, 323), and modulates osteoclast 
differentiation (258). The abundance of this growth factor with such potent effects on 
cells predicts the need for tight regulation of its biological activities. This regulation is 
thought to be achieved through its latency. Since bone is a dynamic, constantly 
remodeling tissue, tight regulation of TGF-ß activity (either in a free or a complex form) is 
crucial. The regulation can be done by: 1. stable TGF-ß binding molecules limiting the 
bioavailability of this growth factor during remodeling, and/or 2. TGF-ß modifications that 
reduces its potency as a growth factor or stabilizes its latency. In bone matrix, there are 
several TGF-ß binding molecules including small leucine-rich proteoglycans, decorin and 
biglycan (260, 275, 276) that may sequester TGF-ß in the matrix and/or diminish TGF-ß 
binding to its cell receptor (277). However, the significance of these interactions in bone 
ECM is not known. Furthermore, potential extracellular modification of TGF-ß that may 
change and/or stabilize the potency is unknown. 
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Here we have demonstrated the direct binding between mature LOX and mature 
TGF-ß1 in vitro and in bone matrix and showed that LOX inhibited TGF-ß1 activity likely 
via its amine oxidase activity. In this study we showed that LOX bound to TGF-ß1 but 
not major osteogenic BMPs found in bone. Using co-immunoprecipitation and GST pull-
down assay, we found that mature TGF-ß1 not LAP was the form that bound directly to 
LOX. As we tried to identify the TGF-ß1 binding site within a LOX molecule, we 
demonstrated that mature LOX, a 32 kDa form of LOX after cleaved by BMP-1 at 
specific sequence, contained TGF-ß1 binding site but not LOX propeptide. Moreover, 
the binding was not affected in the presence of ßAPN, a potent and irreversible inhibitor 
of LOX. It has been proposed that the inhibition occurs by the formation of a “dead-end” 
complex between ßAPN and the carbonyl cofactor of LOX, lysine tyrosylquinone (LTQ) 
(117, 118). The conformational change due to mutations of specific Lys and Tyr in LTQ 
cofactor domain did not affect the binding as well. It implicates that LOX indeed binds 
directly to TGF-ß1 and its LTQ domain is not the binding domain.  
To the best of our knowledge, in bone, LOX was not well characterized except 
the measurement of its activity in crude saline extracts (50). LOX has been reported that 
it can bind to collagen in dentin (221). In preosteoblast culture system, we showed that 
LOX and TGF-ß1 co-localized in the fibrous extracellular matrix. This implicates that 
TGF-ß1 in cultures might be stored closely in the form of SLC and closely associated 
with collagen matrix in which LOX can bind. In bone matrix, LOX and TGF-ß1 appeared 
to be closely associated to collagen and mineral as both were present in E and G2 
fractions of bone matrix. The binding complex of LOX and TGF-ß1 has been identified 
using co-immunoprecipitation in E fraction (mineral-related fraction) indicating the 
presence of the LOX-TGF-ß1 complex in bone.  
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The expression LOX is known to be regulated by TGF-ß1 (75, 76, 138, 141-145) 
but this study is the first to show that LOX in turn regulates TGF-ß activity and signaling. 
It has been well accepted that TGF-ß1 regulates the target genes through TGF-ß 
signaling cascade i.e. Smad3 phosphorylation. Recently, there was a report on a cross 
control of LOX on TGF-ß effects; however, the underlying mechanism was not clear 
(219). Here we showed that LOX directly bound TGF-ß1 and inhibited its signaling 
through amine oxidation evidenced by decreased Smad3 phosphorylation, decreased 
TGF-ß induced gene expression. This was evident since the inhibitory effect was 
diminished by the presence of ßAPN, the LOX inhibitor, or when we transfected cells 
with inactive LOX (LOXdm). In addition the inhibitory effect was not due to H2O2 
byproduct of the LOX oxidative reaction since the inhibitory effect was not altered in the 
presence of catalase, H2O2 scavenger. Previous literature has shown that H2O2 from 
oxidative stress could enhance TGF-ß signaling leading to various effects: i.e. the 
accumulation of extracellular matrix molecules mRNA and protein expression, 
production of proinflammatory mediators or cellular senescense (324-330). Though H2O2 
in this study did not alter the inhibitory effect, it is possible that the H2O2 endproduct from 
LOX oxidative reaction might alleviate the inhibitory effect on TGF-ß1 reflecting a 
moderate inhibition of LOX i.e. the inhibitory effect in exogenous LOX addition. The 
inhibitory effects were also confirmed using MC stable clones over/underexpressing LOX 
and the result showed that Smad3 phosphorylation was enhanced in AS clones (low 
LOX expression) but inhibited in S clones (high LOX expression) after rhTGF-ß1 
induction. 
In MC derived clones overexpressing LOX exhibited less collagen production 
while those underexpressing LOX produced more collagen suggesting the effect of LOX 
on TGF-ß1 induced matrix molecule production (see chapter III). Several reports have 
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shown markedly increased collagen synthesis and abnormal collagen fibrillogenesis in 
ßAPN treated osteoblast cultures (73, 222). The increased collagen production can 
hardly be explained by altered collagen cross-linking since even immature cross-links 
(thus, early forms of cross-links) begin to accumulate only after 1-2 weeks in osteoblast 
cultures (295, 296); however, the current study i.e. LOX regulates TGF-ß1 signaling, 
may explain the phenotype seen in the ßAPN treated osteoblast culture. The 
upregulation of collagen mRNA was also seen in lathyritic animals during the early 
phase of bone fracture healing as well as TGF-ß1 mRNA expression (239). This 
implicates the interaction of LOX and TGF-ß1 in vivo. 
Taken together, our results indicate that for the first time, the signaling of TGF-ß1 
is inhibited by amine oxidase activity of LOX. This proposed mechanism is different from 
the previously reported ones i.e: sequestration of mature TGF-ß to limit the 
bioavailability of this growth factor to its receptor (275) or inhibition of TGF-ß processing 
that decreases its active form or stabilizes its latency (331). This finding represents a 
novel control mechanism of TGF-ß1 function in bone and may provide more insight to 
the mechanism of bone development and remodeling. It will be important in the future to 
determine the specific binding domain of LOX to TGF-ß1 and also the relevant function 
of oxidized TGF-ß1 in bone biology.  
 
CHAPTER V 
 
CONCLUDING REMARKS 
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Concluding remarks 
 It is now evident that LOX substrates are more than immature collagen and 
elastin and that LOX is involved in cellular functions. In conjunction to those, we have 
discovered the followings:  
1. In an osteoblastic cell culture system, overexpression of LOX exhibited lower 
collagen synthesis, smaller collagen fibrils, and markedly delayed mineralization while 
underexpression of LOX exhibited higher collagen synthesis and larger collagen fibrils 
compared to control cells, MC cells and EV clones. These phenomena can be partly 
explained by the fact that the increase of collagen cross-links generated the restricted 
collagen scaffold leading to defective matrix mineralization.  
2. The overexpression of LOX caused suppression of collagen synthesis while 
the underexpression of LOX caused more collagen synthesis at early time-point. The 
LOX overexpression coincided with lower signaling of TGF-ß1 but the underexpression 
enhanced the signaling. The phenomena observed in S and AS clones indicate that LOX 
modulates TGF-ß1 function. 
3. The mature LOX directly binds mature TGF-ß1 both in vitro and in bone marix.  
The binding is not affected by ßAPN or the mutation of LTQ in LOX indicating that the 
binding of LOX to TGF-ß1 does not require LTQ or the conformation generated by LTQ. 
4. The suppression of TGF-ß1 signaling induced either by LOX overexpression 
or an addition of LOX protein was rescued by ßAPN but not affected by catalase. The 
enhancement of TGF-ß1 signaling was observed when LOX mRNA was silenced by 
RNA interference or LOX underexpression. 
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Based on the results that have been observed in the study, it is clear that LOX 
regulates TGF-ß1 signaling through its amine oxidase activity that is important to control 
collagen matrix production/organization and mineralization. The deregulation of such 
control may result in overactivation of TGF-ß signaling leading to bone defects. As TGF-
ß1 is a potent growth factor involved in bone development and remodeling, the current 
study may shed new light on our understanding of bone physiology, pathology and 
treatment. 
Though this study has shown the possible mechanism of how LOX regulates 
TGF-ß1, further experiments are clearly warranted i.e. direct evidence to show whether 
TGF-ß1 is a substrate of LOX by in vitro LOX activity assay, determination of binding 
domain of TGF-ß1 on LOX molecule, identification of oxidized Lys residues on TGF-ß1 
molecule to determine if those Lys are indispensable for the TGF-ß1 signaling. The 
biological significance of LOX-TGF-ß1 complex in bone may be addressed using in vivo 
animal model. The effects of S or AS clones on collagen production, collagen phenotype 
and bone formation could be evaluated using an in vivo transplantation model (285, 
293). The comprehensive analysis of bone phenotypes among LOX deficient animals 
(conventional or tissue specific conditional knock-out), LOX and TGF-ß1 transgenic 
animals should provide valuable information regarding the biological significance of 
LOX-TGF-ß1 interaction. 
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